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Chapter1
General Introduction
Introduction
Coronaryartery bypass graft surgery (CABG)is one of the most commonoperations
performed in the western world. In the UK over 25,000 patients undergo CABG a year
(1). It is a very successful operation with an in-hospital 30 day mortality rate of less than
2% (2). Over 70% ofpatients are free from angina and a further 25% report an
improvement in symptoms(2). One of the problems with CABGis the recurrence of
angina 5 to 10 years after the operation. This occurs due to narrowing of the conduit
(typically the long saphenousvein), due to intimal hyperplasia, and has led surgeons to
use arterial conduits which are notas pronetofailure in this way.
1.1. History of Radial Artery as a Conduit in Coronary Artery
Bypass Surgery
1.1.1 Coronary Artery Bypass Surgery
Thefirst attempt to revascularise the heart using an artery was described by Vineberg in
1964. He described 140 operations where he mobilised the left internal mammary artery
(LIMA),ligated the artery distally, divided it, and implanted the bleeding end into a
tunnel in the left ventricular muscle close to the left anterior descending coronaryartery
(LAD)(3). At a similar time Gordon Murrayreported resecting a diseased part of the
LADandreplacing it with a vascular graft (4). Coronary endarterectomy (excision of
atheroma) or surgical excision wasthe operation of choice in the late 1950’s before
coronary angiography and cardiopulmonary bypass. Longmirereported thefirst direct
anastomosis between the LIMA andthe right coronary artery.
“At the time we were doing the coronary thromboendarterectomy
procedure and wealso performed a couple ofthe earliest internal mammary to
coronary anastomosis. We wereforced into it when the coronary artery we were
endarterectomising disintegrated and in desperation we anastomosedthe left
internal mammary artery to the distal endofthe right coronary artery and later
decided it was a good operation” (5).
With the developmentof direct coronary angiographyin the early 1960’s, surgeons were
able to determine exactly where the narrowing in the coronary artery causing the patients
angina was. It was only a matter oftime before surgeons bypassed diseased parts of the
coronary arteries to achieve normal flow. In 1963, Sabistonfirst performed an aorto-
coronary saphenousvein graft, unfortunately the patient died 3 days later of a cerebral
complication (6). Edward Garrett probably performedthe first successful saphenous vein
graft in 1964 in order to wean a patient from bypass(6).
The work of Rene Favaloro at the Cleveland Clinic in 1967 launched the widespread
application of coronary artery surgery. In 1968 he published a series of 15 patients with
no mortality. At the time of publishing the numberofpatients had risen to 55 with a less
than 2% mortality (7).
1.1.2 Arterial Grafts
Coronary artery surgery widely becameestablished with the long saphenous vein being
the conduit of choice. It was the work of George Green (8) that led to some surgeons
using the LIMA as a conduit. In the early 1980’s the greater long-term patency ofthe
LIMAoverthe long saphenous becameapparent. In 1986 Loop provedbetter patient
survival at 10 years when the LIMA wasanastomosedto the LAD ratherthan the long
saphenousvein in patients with single, double andtriple vessel disease (9). This was
also echoedin the results of other groups (10;11), and its use as a conduit became
widespread. Not only doesthe use of a single IMA increase survival it reduces the
incidence of recurrent angina, late myocardial infarction and the need for further cardiac
interventions (9;12). Now-a-days use of the LIMA occursin over 90% of patients with
disease in the LAD.
The survival benefit of the IMA graft is almost certainly due to its resistance to
atherosclerosis (13). In most studies, early IMA patency is 95%-100% (14;15), but
more importantly the 10 year patency is 95% compared to the 25-50% patency of the
long saphenous vein (16).
With the superiority of both free and pedicled LIMAgrafts over the long saphenous vein
well established, surgeons began using both IMA’s and the search for otherarterial
grafts was on. Additionalarterial grafts used are the radial artery (RA), gastroepiploic
artery (GEA), inferior epigastric artery (IEA), subscapular artery, lateral femoral
circumflex artery, inferior mesenteric artery, and ulnarartery.
Lytle et al have now shown that two IMA’s are better than one in terms of increased
survival and fewer cardiac events (17). This has been confirmed by other authors (18-
20). A meta-analysis of almost 16000 patients performed by Taggart et al. found a
survival benefit at 10 years in patients with bilateral internal mammary arteries (BIMA)
compared to those with a single IMA (hazardratio for death 0.81; 95% CI 0.70-0.94 )
(13). The results of this meta-analysis have to be interpreted cautiously howeveras the
data was from non-randomisedtrials
Oneofthe perceived problems with BIMA grafting is the increased perioperative
morbidity and mortality, especially the risk of sternal woundinfections, and respiratory
morbidity. There is evidence from several large institutions that BIMA grafting does not
increase perioperative mortality in appropriately chosen patients and with surgeons
experienced in the technique (14;17;19-21). In terms of morbidity sternal dehiscence is
the most worrying complication, especially in diabetics. Most studies report an increase
in incidence of sternal woundinfection following the use ofBIMA (22;23) however
others claim that suggestions that BIMA increases pulmonary morbidity are unfounded
(24).
Despite evidence ofclinical and survival benefits ofusing more than onearterial graft
(25) the absence of any large randomisedtrials with long term follow-up, along with the
increased technical demandsofmultiple arterial conduits, has precluded widespreaduse.
In the UK only 15% ofpatients undergoing CABGreceive more than onearterial graft
(26)
Gastroepiploic Artery
Theright gastroepiploic artery (GEA) wasfirst used in myocardial revascularisation by
Bailey and associates in a Vineberg-type myocardial implantation (27). 1n 1974 W
Sterling Edwards used the GEA asa direct bypass graft to the right coronary artery (28).
Thefirst series of patients using the GEA as a conduit for CABG wasdescribed in 1987
(29;30). The GEAhasreported short to midterm patency rates of 80%-97% (28531).
Oneofthe advantages of the right GEAis that it can be used as a pedicledorfree graft.
Inferior Epigastric Artery
The inferior epigastric artery (IEA) is an anatomical continuation of the IMA. It has a
similar internal diameter and histological structure to that of the IMA (32). The use of
the IEA as a conduit for CABG wasreported by Puig in 1988 (33). He later went on to
publish a series of 22 patients who underwent CABGwith the IEA (32). Of the
seventeen patients who underwentearly angiographythe patency rate was 88%. The
two grafts that were blocked were anastomosed directly to the aorta. The size mismatch
betweenthe aortic wall and the diameter of the IEA may explain whythese two grafts
were blocked and an anastomosis onto a pericardial or vein patch maybebetter.
Another wayof avoiding an aorto-IEA anastomosis is to perform compositearterial
grafting (anastomosing IEA to anothergraft). Calafiore has achieved excellent patency
rates using the IEA this way (34). Midterm patencyrates of around 90% have now been
reported for the IEA (35).
The main advantagesofthe IEA areits ease of harvest andits similarities with the IMA.
The disadvantagesofusingit are the postoperative pain a patient will get after an
incision in the abdominal wall. This leads to a decreased willingness to cough,
predisposing them to chest infections. The size mismatch with the aortic wall is another
concern which does not occur with the RA which has a wider lumen andthickerwall.
1.1.3 The Radial Artery
The use of the RA as an alternative conduit for CABG wasfirst reported by Carpentier
in 1973 (36). Twoyears later, he recommendedthe technique should be abandoned
because of a 35% incidence of narrowingor occlusion of this conduit at control
arteriography (Discussion of Carpentier A (37)). These poor results were echoed by
others (38539).
Carpentier thought the initial failure was due to spasm of the dennervated artery
(Discussion of Carpentier A (37)). Others suggested it was due to intimal hyperplasia
(38).
In 1987 Carpentier received a referral in which the recent angiogram showed a RA that
wasoccluded immediately after the original operation and was now patent with no
visible atherosclerosis 15 years after the original operation. This prompted him to
reinvestigate two further patients who had blockedradialarteries initially; both of these
were now patent and disease free (40). These results and the availability ofnew
antispasmodic drugs stimulated Carpentiers’ group to reinvestigate the RA
His group reported a series of 104 patients who underwent myocardial revascularisation
using a RA with excellent results (40). The one year patency was 93.5% (40). Their
improved results were attributed to a more meticulous harvest technique and the use of
antispasmodic agents. The RA washarvested as a pedicle and metal probes as a means
of vasodilatation were avoided. Topical papaverine was used to reverse any spasm
intraoperatively and diltiazem wasusedas an antispasmodicin the postoperative period.
These changesin the methodsofharvesting the RA probablylead to better preservation
of the endothelium resulting from decreased handling andthe lack of probing ofthe
artery. There would also have been a decreased incidence of spasm due to bathing the
graft in a vasodilator solution and the use of calcium channel blockers (41). The
midterm results ofRA grafts are very promising (see table 1.1).
  
  
Author Immediate 1 year 5 year 10 year Method
Patency Patency Patency Patency
Brodman e (42) 95.7% Elective
angiography
Possati GF 93.1% 92%(43) 91.6% Elective
(44) angiography
Acar 99% (40) 92% (40) 83% (45) Angiography
of
consecutive
patients
Buxton RAPCO 95%(less than Elective
trial (46) 70 years old) angiography
86%>70 years
old)
Tatoulis (47) 90.2% Mainly
(mean symptomatic
14.4 angiography
months)
Taco AL (48) 98.9% 95.6% Voluntary
angiograms
Da Costa (49) 96% 100% Elective
angiography     
Table 1.1 Reported Patency of Rates Radial Artery at Various Time
Intervals and Method Used to Measure Patency
 
The RA isa versatile conduit that can be harvested easily and safely, and has handling
characteristics superior to that of otherarterial grafts (50). It is long enough to
comfortably reach any coronaryartery from the ascendingaorta. The size of the
proximal end of the RA is bigger than that of other arterial conduits, such as the IMA
and IEA,this makes a proximal anastomosis to the wall of the ascendingaorta easier and
one does not have to worry as much about a size mismatch.
The RA hasa great ability to adapt its diameter to the flow necessary (flow mediated
vasodilatation and vasoconstriction). In the presence ofa large run off (occluded or
tightly stenosed coronaryartery supplying a large territory) the artery dilates. However
the reverse happensin areas of low flow, the RA contracts reducing its internal diameter:
this behaviouris evident angiographically, the so called string sign. This phenomenon
has led someauthors to recommendthat the RA should only be used as a conduit to graft
arteries with a high run off (34).
Use of the RA doesnot increase the complexity or morbidity ofCABG (51). Its harvest
is associated with minimal significant morbidity. Although up to 67% ofpatients
complain of some sensory symptomsrelated to RA harvest, no patients said these
symptomsinterfered with daily activities (52). Patients report sensation loss far more
often than it can be objectively measured. Royseet al. report only 2.1% ofpatients
having detectable sensory loss in the distribution ofthe lateral cutaneousnerveofthe
forearm and 0.3% in the distribution of the superficial branch of the radial nerve (53).
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The differences are probably due to patients perceiving scar tightness or hypersensitivity
as sensory symptoms.
Patients rarely complain of any functional impairmentofthe arm following RA harvest.
Saeed ef al. quote an incidence of3% of patients complaining of mild limitation in hand
activity (52). Functional assessment of the arm following RA harvest reveals only slight
decrease in strength or sensory loss. Royse et al. found grip strength to be 4.8% less and
finger pinch strength to be 5.1% less when compared with the non-operated arm (53).
Onehas to rememberthat it was usually the non-dominant arm that was used for RA
harvest and these small differences may merely reflect the difference between the two
arms. The incidence of woundinfection rate following RA harvest is between 0 and 6 %
(52). Numerous studies have shownthis to be less than that following saphenousvein
harvest (52).
Oneofthe most feared complications of RA harvest is hand ischaemia (54). This
howeveris extremely rare. Out of 6,646 patients having at least one RA harvested
Tatoulis et al. report only two patients with finger tip ischaemia (47). Both of these
patients had scleroderma and Raynaud’s phenomenon, which many surgeons would say
wasa contra-indication to RA harvest.
Preoperative and postoperative index finger pulse oximetry reveals an increase in
saturation following RA harvest and CABG,both in operated and non-operated index
fingers (53). This probably indicates the SpOfor the whole patient increased following
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surgery. There is certainly no decrease in oxygen saturation in the hand following RA
harvest. This correlates with the extremely low incidence ofhand ischaemia.
Although the results of the RA as a bypassgraft are excellent, the RA has one main
drawback, that of spasm. Spasm is the spontaneouscontraction ofthe artery. It can lead
to myocardial hypoperfusion post-operatively leading to perioperative myocardial
infarction (MI) and death. The RA isclassified as a type III functional artery (55). This
type of artery is more reactive to vasoconstrictors than somatic arteries located in the
body wall (type 1, such as IMA andIEA)or splanchnicarteries (type II e.g. GEA).
Spasm occurs frequently during harvesting of the RA so that pharmacological agents
(vasodilators) are required intraoperatively to relieve this prior to grafting. These can be
applied topically to the RA once harvested,prior to grafting. Spasm mayalso occurin
the postoperative period. Cable et al. quote an incidence of spasm in 5 to 10% ofRA
grafts postoperatively (56). Spasm in the postoperative period must be treated with
intravenousororal vasodilators or be prevented by the use of long acting topical
pharmacological agents at the time of surgery. The reported incidences of spasm are
shownin table 1.2.
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Group Incidence Time Following Surgery
Acar(40) 4-5% First three weeks
Manasse(57) 10% Mean 24.3 days
Iaco (48) 0% Mean 18 days
Calafiore (34) 1.3% Within 12 months of op
Da Costa (49) 10% Onhospital discharge
Chen (58) 4.3% Mean 11.6 weeks  
Table 1.2 Reported Incidence of Spasm andInterval Following
Surgery Measured
1.2 Preoperative Assessmentof the Hand Circulation
The Allen’s test is the most commonly usedtest to assess the collateral circulation prior
to RA harvest. The ulnar and radial arteries are compressed at the wrist for 30 seconds
to induce hand ischaemia. Blood is evacuated from the hand by clenchingthe fist. The
ulnarartery is released and if hyperaemic reperfusion (change in colour from white to
red) at the tips of the thumb andindex finger occurs in 5 secondsorless thetest is called
normal and the RA harvested. If reperfusion occurs in 6-10 secondsthenthetest is
called equivocal and mostly the RA is used. If it takes longer than 10 secondsthen the
test is deemed abnormal and the RA not used.
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Other methods usedto assess the hand circulation include doppler studiesanddigital
plethysmography(59).
1.3 Harvesting of the Radial Artery
The arm andchest are prepared and draped together. The arm is placed on an arm board
attached to the operating table so that no traction on the arm occurs whenthe table
height is varied.
The incision extends from 1cm medial anddistal to the biceps tendonat the elbow,to
1cm medial and proximalto the radial styloid process. It should take the shape of‘a
lazy S’. Diathermyis used to divide the tissues to the deep fascia. Care is taken to
avoid the lateral cutaneous nerve of the forearm which crosses the RA from lateral to
medial nearthe distal extremity of the incision. The deep fascia is then divided along
the medial edge of the brachioradialis muscle.
Deepto the brachioradialis muscle lays a well defined fascia surrounding the RA andits
venae commitantes. Oncethis fascia is divided the RA lies within loose areolar tissue
andis very easily harvested. The deep fascia and the fascia surrounding the RA fuse in
the distal third of the forearm and should be divided together. The branches of the RA
are then divided using a combination of diathermy and metal clips. Some people prefer
to avoid the use of diathermyas they feel this may cause damage to the RA. Others feel
the use of metal clips increases the handling of the RA and hence spasm. The harmonic
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scalpel may be used to harvest the RA and has been shownto reducecollateral damage
(59;60). During harvesting neither the artery or the venae commitantes on either side of
the RA should be grasped in order to prevent spasm.
The RA is divided proximally first, distal to the origin of the ulnar artery. If the full
length of the artery is not required then the large muscular branch to brachioradialis can
be preserved. Once divided proximally, one checks for back flow from the divided
proximal end of the RA to confirm adequate collateral circulation, the squirt test (61).
Theartery is then divided distally and stored ready for grafting.
The proximal and distal stumpsare ligated and transfixed. The fat and skin, but not the
deep fascia is closed. The arm is then bandagedand placedbythepatients’ side and the
operation continues.
1.4 Morphology, Physiology and Pharmacologyofthe Radial
Artery
The forearm and handreceivesits blood supply from the radial and ulnar arteries. The
RA commencesat the bifurcation of the brachial artery, just below the elbow. It passes
along the radial side ofthe forearm to the wrist. It then winds backward, around the
lateral side of the carpus, beneath the tendons of the Abductorpollicis longus and
Extensor pollicis longus and brevis to the upper end of the space between the metacarpal
bonesofthe thumb andindexfinger. Finally it passes forward between the two heads of
the first interosseous dorsalis, into the palm of the hand, whereit crosses the metacarpal
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bonesandat the ulnar side of the hand it unites with the deep palmar branch ofthe ulnar
artery to form the deep palmararch.
There are extensive anastomoses between the branchesofthe radial and ulnararteries.
The superficial and deep palmararches are the most important of these circuits because
they provide the blood supplyto all of the fingers (62). It is these anastomosesthat
allow the handto still receive an adequate blood supply following harvest of the RA.
Variations in the blood supply to the hand are common. The deep palmararch is
incomplete in 10% ofhands and the superficial palmar arch incomplete in 34% ofhands
(62). Ruengsakulrach ef al. in the 50 hands they studied found no cases of both an
incomplete deep and superficial palmar arches (62). From an anatomical point of view it
is therefore safe to remove the RA from its origin proximally, andto the level of the
wrist distally. This is backed up in the literature as reports ofhand ischaemiaare rare
(54). In the Melbourne experience of over 6000 RA’s any hand ischaemia that occurred
was in patients with vasomotordisorders (47).
Whenonelooksat the biological characteristics of any artery it is helpful to divide it up
into the structure and function of the endothelium andthat of the smooth muscle. One
must rememberthough that these two components do not act independently.
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The RA is a very muscular artery that has a media rich in leiomyocyte (63). In the RA
myocytes within the media are organised in tight layers, whereas in the IMA there is
irregular organisation of myocytes with a loose structure of connectivetissue andelastic
fibres (56).
The vasa vasorum of the RA do not penetrate into the media, oxygen and nutrients are
provided by diffusion (63). This suggests that transposition ofthe artery as a free graft
should not have adverse ischaemic implications.
Regionalvariations occur in both the functional and morphological characteristics of the
RA (64). This regional variation should be taken into consideration when choosing a
section ofRA for a bypass graft. There is more smooth muscle in the wall of the
proximal RA thanthat of the distal RA, This is reflected in the greater contractility of
the proximal RA to KCI (64). Despite the increased contractility of the proximal RA it
is usually the distal end that goes into spasm in clinical practice (65). The explanation
for this could be that any contraction of the RA hasa greater effect on the smaller distal
end.
The reason for superior performanceofarterial grafts is not fully understood. The IMA
seemsto be free of the intimal thickening noted in coronary arteries with advancing age
(66;67). The preserved and perfused vasa vasora of the IMA graft may be factorthat
contributes to the increased patency. Another factor that may contribute to the long-
term patency of the IMAgraft is the endothelial function (68). Prostacyclin production
17
from the IMA endothelium, when comparedto that of the saphenousvein is greater (69).
He and Yangcould not detect significant differences in endothelial function between the
RA and IMA(68).
It is well reported that saphenousvein grafts are prone to the developmentofintimal
hyperplasia, followed by atheromatous change. This characteristic has been
demonstrated histologically and is responsible for the poor long-term results of this
conduit (70;71). Hagiwaraet al. describes a method to study coronary artery bypass
grafts in vivo using intravascular ultrasound imaging. They studied 15 RA grafts and
found no changein thicknessofthe intima or the media in the mid-term (70). With such
small numbersdefinitive conclusions regarding patency or comparisonsto other grafts
are difficult to make and the authors' conclusion that structural changes rarely developed
in RA grafts in the early years after surgery is speculative.
Various vasoconstrictors have been suggested to be the cause of spasm in humanarterial
grafts (72). Studies have shownthat the RA hasa greater contractile response than the
IMAto vasoconstrictors including noradrenaline (NA), endothelin 1 (ET 1), serotonin
(5-HT), and angiotensin I and II (68;73-75). He and Yang demonstratedthat the
contractile force to KCl, normalised for circumference, was similar in the RA and IMA
(68), However, even when onehas normalised for vessel wall thickness, NA,
vasopressin, angiotensin II and ET 1 produce greater increases in tension compared to
the IMA,suggesting that the increased contractility in the RA is receptor mediated (68).
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To support this their study showedthat there wasnoincreasein sensitivity of the RA
compared with the IMA to ET1 and angiotensin II (68).
For these reasonsit is obviously important that we need a detailed knowledgeofthe
characteristics of the receptors in the RA. The human RA is an a-adrenoceptor
dominantartery with little B—adrenoceptor function (76). This absence of
B—adrenoceptor function differs from that of the IMA (77). Also in the RA a-
adrenoceptorsare present (76). B—adrenoceptors mediate relaxation oflargearteries.
They tend to contract when B—blockers are given because the S—mediated relaxation is
eliminated as reported in coronary arteries (78). The absence of B—adrenoceptors clearly
demonstrate that B—blockers will not cause spasm in the RA.
Post-junctional a-adrenoceptors are composed ofa and a2 subtypes. The contribution
of a-adrenoceptorto drug induced contraction dependsonparticular blood vessels and
species, as well as the diameterofthe blood vessel (79;80). In the RA, drug induced
contraction is via both a, and a2 subtypes (76). It is unknown which subtype of
adrenoceptors mediate neuronal sympathetic vasoconstriction in the human RA.
Medgett and Langer (81) reported that a-adrenoceptors do not mediate neuronal
sympathetic vasoconstriction in the cat middle cerebral artery as they are located extra-
junctionally. However morerecent reports have shownthat postsynaptic 2-
adrenoceptor can be involved in the vasoconstrictor response to sympathetic nerve
stimulation to a significant (82) or even predominantlevel (76;83).
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Other receptors present on the RA that may contribute to spasm include the 5-HT,
receptor for 5-HT, endothelin A receptor for ET I (84) and the AT-1 receptor which
mediates angiotensin II induce contractions (73).
1.5 Mechanisms ofspasm
Thetrue incidence of vasospasm in the human RA is difficult to determine as many
cases may go undetected (85;86). Reports of perioperative ischaemiain patients with
RA bypassgrafts (87) and the observed reduction in postoperative markers of MI in
patients receiving RA grafts treated with PhB as compared with those treated with
verapamil/ glyceryl trinitrate (88), would support the need for effective, postoperative
vasodilator therapy.
Below is the CT scan of a patient who was being followed up for mediastinal
lymphadenopathythat had been found on a pre-operative CT scan. At 6 weekspost-
operative no flow in the RA canbeidentified, its position being identified by surgiclips
(figure 1.1a). However at 3 months postoperative good flow is seen in the graft (figure
1.1b).
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 Radial artery graft from
descending aorta to
obtuse marginal vessel.
Surgiclips identified but
no contrast in artery
  
     
Figure la — Theradial artery can beidentified by the position of the surgiclips, but no
contrast is present in the artery i.e. the artery is blocked or in spasm.
6 weekslater
contrast is present
in the artery
Figure 1b — Contrast is now present in the radial artery showing that it was in spasm,not
blocked 6 weeksearlier.
Figure 1.1 - Transaxial views of CT scan of the chest of a patient who had redo
coronary artery surgery. A RA was anastomosed from the descending aorta to the
1“ obtuse marginal vessel. A CT scan performedpre-operatively, to assess the
position of the internal artery behind the sternum, had identified enlarged pre-
tracheal lymph nodes. These were followed up on interval CT scans at 6 weeks
(figure 1a) and 12 weeks post-operatively (figure 1b).
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Spasm can occur both during harvesting and after the graft is connected, the aetiology is
likely to be multi-factorial. Factors probably involved in the mechanism of spasm
include surgical trauma,locally released vasoconstrictors, neural factors, and circulating
hormones
Oneofthe problemsabouttrying to understand the mechanismsof spasmis that isolated
tissue assays can only determine what factors have the potential to cause spasm not the
causeofit in vivo.
The mostlikely cause of spasm at the time of harvesting is surgical trauma. Smooth
muscle in the wall of the RA will contract in response to mechanical stimulation during
harvesting and grafting. It was changes in the harvesting technique along with the use of
calcium channel antagonists that led to the revival of the RA as a conduit for CABG
(40). Surgical trauma can be minimised by harvesting theartery as a pedicle (along with
accompanying veins and areolartissue) rather than skeletonising it. Taggart et al. has
described successfully using the RA after skeletonising it. This is possible if meticulous
surgical technique is used and vasodilators used to reverse any spasm priorto grafting
(89). However, wefeel that spasm is best managed by prevention, rather than treatment
after it has occurred, and therefore do not advocate the use of this technique. Another
cause of spasm in the perioperative period may be the temperature changes the RA may
experience (90). The RA should be stored in a solution at 37°C after harvesting, prior to
grafting, to prevent any temperature induced spasm.
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The aetiology of the cause of spasm in the postoperative period is moredifficult to
determine. Undoubtedly, levels of vasoconstrictors are raised in the postoperative
period. These vasoconstrictors include NA, adrenaline, angiotensin II, vasopressin, ET
I, thromboxaneAg,prostaglandin F,,, and 5-HT (91). Anyorall of these factors may be
responsible for spasm. One of the problems with this theory of spasm is that although
raised levels of these vasoconstrictors are present in the postoperative period they reach
nowherenear the ECso for these compoundsin vitro (see table 1.3), and also the levels
of these compoundsreturn to normal within a few daysafter surgery, spasm maystill
occurafter this time.
 
  
Vasoconstrictor Post-operative ECs in RA
plasmalevel
Endothelin 1 0.086nM (74) 117nM (68)
Angiotensin II 36pM (74) 3.5-6.9nM (68;73)
Noradrenaline 0.17uM (74) 1.8uM (92)
Vasopressin 100pg/ml (93) 1.9nM (94)  
Table 1.3 — Comparisonsofin vivo levels of vasoconstrictors
following CABGandthein vitro ECs» of the vasoconstrictor on the
human RA
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Although the plasmalevels of these vasoconstrictors do not reach levels that would
cause a contraction in vitro, local levels in vivo may be higher than plasmalevels. ET I
is a potent long acting, calcium dependent vasoconstrictor produced by endothelialcells
(95). Although small amountsare present in the plasmait acts locally (91). Endothelial
cells are activated during CABG by mechanical and chemical stimuli such as thrombin,
bradykinin and adrenaline. Activation leads to increased ET I production (96).
ThromboxaneAzis derived from platelets. Platelets are activated during
cardiopulmonary bypassleading to an increased production and release of thromboxane
A» (91). Platelets may adhere to any damaged endothelium in the RA releasing
thromboxane Ay,at high local concentrations.
As well as endogenous vasoconstrictors, endogenousvasodilators such asnitric oxide
and natriuretic peptide are released after CABG. Therefore, exogenous vasoconstrictors
are often required to maintain the patients’ blood pressure postoperatively. Commonly
used vasoconstrictors include NA and phenylephrine. Vasopressin is becoming more
commonly used as a vasoconstrictor following cardiac surgery.
Vasopressin is synthesised in the magnocellular nuclei of the hypothalamus. It is then
axonally transported to the neurohypophysis whereit is released into the blood.
Vasopressin is a critical controller ofbody water balance. Its primary actionis to
increase water reabsorption by the kidney. Its output is primarily regulated by the
electrical activity of the magnocellular neurones. During dehydration the firing of these
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neuronesis increased via activation of peripheral, central and intrinsic osmoreceptors
sensing a rise in plasma osmolarity (97).
Arginine vasopressin (AVP)haslittle vasoconstrictor effect in haemodynamically
normal subjects but is a potent vasoconstrictor in states associated with arterial
hypotension (98;99). AVPis one of the most potent coronary artery vasoconstrictors
known (100). AVP has a great propensity to cause vasospasm in coronary bypass
conduits (101). This occursas a direct effect evoking contraction of the vascular smooth
muscle via the V1 receptor (102) and also byfacilitating sympathetic neurotransmission
and promotesthe constrictor effects ofNA (103).
Vasodilatory shock induced by cardiopulmonary bypass, is usually mild, and requires
low doses of vasopressor support to maintain perfusion for a few hours postoperatively.
However in 8% of cases, a more severe state of shock develops necessitating high dose
vasopressor therapy (104). The administration of high dose catecholamine vasopressors
is associated with complications related to end organ perfusion and their effectiveness is
limited by catecholamineresistance (105). Vasopressin levels have been shown to
increase morethan 6 times following CABG,andcanreach levels of 100pg/ml(93).
Patients with vasodilatory shock following CABG,although having AVP levels within
the normal range, have been shownto have inappropriately low levels ofAVP for the
degree of hypotension present (104). These findings have led to some authors
recommending the use of exogenousvasopressin to treat vasodilatory shock following
cardio-pulmonary bypass(104).
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Plasma NAlevelsare raised in the postoperative period (91). The NAis derived from
sympathetic nerves. The RA has a dense network of sympathetic nervesin its wall. In
this thesis I will investigate whether degenerating nerve endings in the wall ofthe RA
have the potential to release sufficient NA to cause spasm.
Noradrenergic Transmission
Synthesis of NA
Thestarting material is dietary L-phenylalanine. This is absorbedin the small intestine
and oxidized by hepatic phenylalanine hydroxylase to form L-tyrosine. Thisis
circulated in the bloodstream and actively taken up into the cytoplasm of noradrenergic
nerves. Here it is converted to dopamine. Dopamineis actively transported into the
transmitter storage vesicles. Hereit is oxidised to NA.
Storage of NA in vesicles
Endogenous NAisstored in vesicles which are formed in the cell body and transported
to the axon terminals by axoplasmic flow. Within the vesicle storage ofNA is aided by
the presence of adenosine triphosphate (ATP) (forms a weak complex), a
sulphomuccopolysaccharide and a soluble protein called chromogranin. The resistance
to diffusion is provided by the vesicular contents and the continued operation ofthe
amine uptake process in the vesicle membrane.
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Release of NA from Sympathetic Nerve Endings in vitro
NA can bereleased from nerve endingsbyelectrical stimulation or by chemical
treatments which either destroy the nerve terminalitself or displace the stored NA.
Tyramine is a compoundwith a similar chemical structure to NA. (Figures 1.2 and 1.3)
It has lost the catechol-OH group and the B—OH group.
OH
NH>
HO
OH
Figure 1.2 - Chemical structure of Noradrenaline
NH>
HO
Figure 1.3 - Chemical structure of Tyramine
Tyramine displaces NA from its storage vesicle in sympathetic nerve endings. We will
be stimulating human RA rings with tyraminetoseeifit elicits a contractile response.
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Synergism of vasoconstrictor responses
Despite the levels of vasoconstrictors in the plasmabeing insufficiently raised to cause a
contraction of the RA in vitro alone, it has been shownthat there is a synergistic effect
between somevasoconstrictors e.g. NA and vasopressin. It may therefore be a
combination of vasoconstrictors that are the cause of spasm in vivo. This will be briefly
investigated in the appendix ofthis thesis.
1.6 Prevention and Treatment ofSpasm
Various different drugs have been usedto prevent and treat spasm. Pharmacological
strategies to prevent spasm usually consist of an intra-operative strategy and a
postoperative strategy. The intra-operative strategy is used to treat any spasm that
occurs during the harvesting of the RA. Drugsare applied topically to the RA prior to
grafting. Since these drugs do not enter the systemic circulation they can be used in high
concentrations. Postoperative strategies are used to prevent spasm after the operation.
They generally consist of giving a vasodilator via intravenous infusion until the patient
can take oral medication. The length of time a patient should take antispasmodic
medication is controversial. Some commonlyusedstrategies are shownin table 1.4.
Morerecently PhB,an irreversible « adrenoceptor antagonist has been used to prevent
spasm. This offers a novel approach to prevent spasm because the RA is treated prior to
grafting and theeffects of the drug should still be present in the postoperative period. In
this thesis I will investigate the duration of action of PhB andlookat other irreversible
drugs that might havea role to play in the prevention and treatment of spasm.
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Group Operative Strategy Post-operative Strategy
Acar(45) Blood and papaverine Intravenousdiltiazem
(0.1mg/kg/h) then oral
(250mgdaily)
Cable(56) Lactated Ringer’s, papaverine
and verapamil
Buxton (46) Papaverine (1mM)in 50% Intravenous milrinone
blood, 50% ringers lactate (loading dose 25y12/Kg then
0.25ug/Kg/min for 12-18
hours) then oral amlodipine
(2.5-5mg)
Calaforie(34) Papaverine 1mg/ml in normal Intravenousdiltiazem
saline (4mg/h) then oral diltiazem (
60mg tds for 1 month)
Dietl and Benoit(65) Papaverine and diltiazem if
spasm noted
Diltiazem (0.1mg/Kg/h for
48hours them 120mg-240mg
oral for 6-12 months)
  Reyes(106) Papaverine 1mg/ml blood Diltiazem (loading doseisnow 0.05 mg/kg followed bya continuousinfusion of 0.15to 0.2 pg/kg" / min)He and Yang(107) Verapamil (30uM) Intravenous verapamil nitroglycerin (30M) solution  (0.5mg/h then 240mgoraldaily for 1 year)
Table 1.4 Different Strategies Currently Used To Prevent Spasm.In
someincidences no dosesare givenin the table because doses
were notstated in the referenced paper
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1.6.1 Glyceryl Trinitrate
This is a lipid soluble drug that penetrates cell membranesdelivering thenitrite ion and
free radical nitric oxide (NO)into the cytoplasm. NO inhibits receptor stimulated
calcium release from intracellular stores and reduces calcium influx by hyperpolarising
the cell membraneor inhibiting voltage gated calcium channels (86;108). In addition,
NO promotes the reuptake of calcium into stores and calcium extrusion, as well as
accelerating myosin light chain phosphorylation (86;109). This effectively meansthat
GTNopposesboth agonist mediated contraction and subsequent sensitisation caused by
the activation of rho-kinase, as NO inhibits Rho A activation.
GTN maybeapplied topically to the RA prior to grafting to relieve any spasm present
following harvesting, given intravenously in the perioperative period to prevent spasm,
or orally for a period of time following the operation to prevent late spasm.
Average therapeutic plasma concentrations of GTN are 2x10°M (15-20pg/min
intravenously) (110).
Both GTN andisosorbide dinitrate have been shownto significantly reduce KCl and NA
mediated contraction of the RA (56). Isosorbide dinitrate was not as effective as GTN at
reversing established KCI induced contractions of the RA (56).
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Chandaetal. found GTN (2x10° M) was equally effective at reversing spasm dueto a
combination of vasoconstrictors when comparedto a combination of GTN (1x10° M)
and a calcium channelblocker (74).
GTNhasbeen shownto be superiorto diltiazem at causing vasodilatation of the RA
both in vitro and in vivo (111;112). GTN is well tolerated in the postoperative period.
Shapira et al. found that all patients in their trial randomisedto receive intravenous GTN
(n=84) were able to tolerate it, as were the 5 patients that crossed over from the
intravenousdiltiazem group becauseofside effects (112). Despite finding GTN to be
better tolerated than diltiazem, and to be better at causing relaxation of the RA in vitro
and in vivo, Shapira failed to show anyclinical differences, such as mortality,
perioperative MI, creatinine kinase MB isoenzymelevel, or abnormal perfusion to the
RA territory on thallium-221 stress testing, between patients receiving GTN and
diltiazem that could be relate to spasm (112) The reason forthis is presumably the
relatively small numbersin their study.
Oneofthe problems with GTN is that the vasodilatory effects are rapidly blunted
becauseofthe developmentofnitrate tolerance (1133114). Long-term treatment has
been shownto be associated with cross tolerance to other endothelium-dependent
vasodilators such as acetylcholine (115). Cross tolerance is probably due to an increased
production of reactive oxygen species leading to an enhanced breakdownofendothelial-
derived nitric oxide (116). Protein kinase C has been shownto beactivated in patients
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on GIN. This may suggest a potential role for protein kinase C inhibitors in preventing
the developmentofnitrate tolerance and cross-tolerance.
Another one of the major problems with GTN isits relatively short duration of action.
Mussaet al. found that verapamil/GTNsolution wasineffective after 5 hours (117).
1.6.2 Calcium Channel Blockers
These drugsall act by binding to the a, subunit of the L-type calcium channel, whichis
the main pore forming unit of the channel (118). The L-type calcium channel is present
in cardiac muscle, vascular smooth muscle, non-vascular smooth muscle and other
tissues. They inhibit the influx of the Ca** into the cytoplasm. In vascular smooth
muscleanincrease in cytosolic Ca~" leads to contraction. Therefore blockage of calcium
entry into the cytoplasm will favour relaxation.
Calcium channel blockers are very effective in preventing or reducing the contraction to
depolarising agents such as K”. This is because calcium channel antagonists block
calcium entry into the cell by blocking voltage operated calcium channels whichis the
major mechanism ofthe constricting action of depolarising agents. They are less
effective at blocking contraction mediated via G-protien coupled membranereceptors
such as vasopressin, angiotensin II, ET I and NA (41).
Manyauthors advocate the routine use of calcium channel blockers when the RA is used
in CABG (34;40-42;65). The problem with these drugs is that they cause bradycardia,
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hypotension due to a reduced cardiac output or rhythm disturbance andsotheir use is
not advocated by others (119). Shapira et al. (120) found that 40% ofpatients receiving
diltiazem post-operatively required temporary pacing, resulting in a longer intensive care
unit stay. Diltiazem is also more expensive than GIN. 24 hours intravenousdiltiazem
is 10 times more expensive and 6 monthsoral diltiazem twice as much (112). There is
also the expense of an increased intensive care stay and the expense ofan increase in the
incidence of temporary pacing to be taken into consideration.
The mosteffective group of calcium channel blockers at preventing spasm are the
dihydropyridine group (121). It is the 1,4 dihydropyridine ring that probably gives them
their increased vascular selectivity properties (122). Amlodipine has a moreionic
charge than nifedipine making it more vascularselective, having less of an effect on
myocardial contractility and a longer duration of action (122). These advantages may
make amlodipine moresuitable as an antispasmodic, especially in patients with an
impaired left ventricular function, although nifedipineis a slightly better vasodilator in
vitro (123). Of the various calcium channel blockersdiltiazem is the least potent (124).
Cable et al. found that diltiazem and verapamil did not significantly alter the contraction
ofRA rings to KC] and NA, howevernifedipine decreased the response to KC] and NA
throughout the concentration response curve (56). Nifedipine wasnotas effective as
GTNat reversing established KC] induced contractions of the RA (56).
Angiographically provoked spasm by 5-HTinfusion also suggeststhat diltiazem is
ineffective at treating spasm (57).
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Acaret al. recommendthe long-term prescription of calcium channel blockersin
patients receiving a RA graft (45). Howeverin this study only 60% ofpatients
continued with the calcium channel blocker and no difference in patency of the RA graft
could be detected between the two groups (45). Possati (44) also found no difference in
the patency of the RA at 10 years in patients who continued the calcium channel
blockers beyondthe first year.
Average therapeutic plasma concentrations
Nifedipine 0.28uM (125)
(10-20mgorally 8 hourly or 5-15 t.g/kg/min intravenously)
Diltiazem 560nM (125)
(60-90mgorally 8 hourly or 75-150 .g/kg/min intravenously)
Verapamil 0.22 uM (125)
(80-160mgorally 8 hourly or 150 pg/kg/minintravenously)
Nicardipine 5610 nM (126)
(1 pg/kg/min intravenously)
Since calcium channel blockers provide vasoconstrictor-selective vasodilatation in
humanarterial grafts, He and Yang (41) proposed using a combination of verapamil and
GTN. This combinesthe advantagesofthe highly selective blockade to voltage-
dependent calcium channels and longerlasting effects of calcium channel blockers with
the rapid onset, short acting non-specific effect of GIN. They had previously shown
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this combination to be useful in other conduits used for CABG (127;128). They found
that a solution of verapamil and nitroglycerin induced morerapid relaxation of the RA
than papaverine (41) and later went on to show it was less harmful to the endothelium
(107).
1.6.3 PhosphodiesteraseInhibitors
Phosphodiesterases are a family of isoenzymesthat are responsible for the breakdown of
phosphodiesters such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP). Type III phosphodiesterase inhibitors e.g. enoximone,
milnirone or amrinoneprevent the breakdown of cAMP. In cardiac muscle the
increased intracellular concentrations of cAMPcause an increase in myocardial
contractility. Increased cytoplasmic concentrations of cAMPin smooth musclecells,
leads to the reuptake of Ca’* into the sarcoplasmic reticulum,and therefore relaxation.
This ability to relax smooth muscle hasled to the use of phosphodiesterase inhibitors to
prevent spasm in the RA.
Papaverine is a smooth muscle relaxant whose modeofaction is poorly understood It is
believed to act predominantly as a phosphodiesterase inhibitor (129) although it also
decreases calcium influx (130) and inhibits release of calcium from intracellular stores
(131).
The problem with papaverineis that it has consistently been shown to damage the
endothelium (132). Although this work has been mainly on the IMA and long
saphenousvein one would expect similar damage to occurto the endothelium of the RA.
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Dipp et al. showed that papaverine was more harmfulto the endothelium of the RA than
PhB (129). Papaverine has a duration of action of less than 1 hour (117). This damage
to the endothelium and short duration of action limits its usefulness as an antispasmodic
in RA conduits.
It has been shownthat enoximoneand milrinone are capable of causing nearly complete
relaxation to the contractions produced by thromboxane Az mimetic U46619, NA or KCl
in the IMAin-vitro (1333134). This effect of enoximone waspotentiated by dobutamine
(133). Liu et al. found milrinone to be more potent than papaverine but not as potent as
GTNorsodium nitroprusside at preventing spasm (134). Any inhibitory effect of
milrinone occurred as a decrease in the maximal responsenotas an increase in the ECs
indicating its effect is directly on the smooth muscle.
Thetherapeutic levels of enoximone are 7.3x10°M. This is achieved with a bolus of
1000 pg/Kg followed by an intravenous infusion of 10ug/Kg/min (135). This level only
caused 0-30% relaxation in IMA rings (133). To back the evidence up that enoximone
maynot be a useful vasodilator at therapeutic concentrations Cracowskiet al. have
previously shown noincrease in IMA bloodflow whenthe patient was given a bolus
injection of 200j1g/Kg enoximone(136).
In contrast to enoximone, milrinone maybea clinical relevant vasodilator on human
IMA(137). Plasma concentrations of milrinone are ECs of 167ng/ml (7M) (138).
Milrinone has the advantage over other antispasmodicsofbeing positively inotropic.
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Alsoasits action is endothelium independent, it may be useful to prevent spasm due to
endothelial dysfunction. He and Yang have shown milrinoneto be a potent vasodilator
of the RA at therapeutic levels (139). They found milrinone caused an increase in the
ECso and a reduction in the maximal response to KCl, phenylephrine and U46619 (139).
This differs from what has been shownin the IMA (134).
Sildenafil is a selective inhibitor of type5 cGMP phosphodiesterase. It is used to treat
erectile dysfunction in men (140). Inhibition of cGMP phosphodiesterases leads to an
increase in intracellular cGMPin vascular smooth muscle. This reducesintracellular
calcium levels by stimulating Ca’*-pumping adenosinetriphosphatases, or by opening
Ca’*-activated K* channels (141). Sildenafil has been shownto cause significant
relaxation in the human RA in vitro (142). The relaxation of the RA by the NO donor
sodium nitroprusside was amplified in the presenceofsildenafil (142). Type 5
phosphodiesterase is not present in the human myocardium,therefore sildenafil is not a
positive inotrope unlike the type 3 phosphodiesterase inhibitors. Beforeits use clinically
morestudies are neededto assess its efficacy compared to other antispasmodics.
1.6.4 Phenoxybenzamine
Phenoxybenzamine (PhB)is a non-competitive antagonist of the « adrenoceptor. It is a
B-haloalkylaminerelated to the nitrogen mustards. It acts by irreversibly alkylating the
a adrenoceptor on the cell membrane.
Taggart et al. first described the uses of PhB as an antispasmodic (143). He later went
on to showthat its duration of action wasgreater than that ofpapaverine and less
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harmful to the endothelium (129). It has also been shown that PhB wasmoreeffective
and lasted longer than verapamil/nitroglycerin solution (117).
Velez et al. found that a much smaller dose of PhB wasnecessary to observe a maximal
effect in canine radial arteries (144). They observed a maximaleffect at a dose of 1uM
compared to the 6mM that Taggart recommended using. Also they achieved this
maximaleffect after a 30 minutes treatment period compared with the one hour period
described by Taggart (143). Corvera et al. observed a maximaleffect at ImM in human
radial arteries with a 30 minute incubation period (145). This shorter treatmentperiod is
importantas it is what happensin clinical practice.
NAis a mixed a and B adrenergic agonist. Antagonism of the a adrenoceptors not only
prevents contraction of the RA due to NA,it unmasksthe vasodilatation component of
the B adrenoceptors. Stimulation of the B adrenoceptors by NA after a adrenoceptor
blockade by PhBin the RA will lead to vasodilatation (145).
A similar thing is seen with another commonly used inotrope in cardiac surgery,
dopamine. In the peripheral vasculature dopamineexerts its effects via the D;
dopaminergic receptor and o adrenoceptors. Inhibition of the a adrenoceptor by PhB
will unmask the D, effect of dopamine which will lead to a mild vasodilatation (146).
The duration of action ofPhB in the human RA is unknown. Velez et al. found that the
effects ofPhB lasted 48 hours in canine RA rings that were stored in an incubator (144).
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The lack of regeneration of «-adrenoceptors in this experiment may be dueto the flaccid
conditions the rings were incubated under. The response to phenylephrine returns fully
within 48 hours in mouseaorta treated with PhB (147).
PhBhas been suggested by someasthe sole prophylactic strategy for the prevention of
spasm in the RA. However, the levels of several other vasoconstrictors are raised
following CABGandtheir contribution to the development of spasm should not be
overlooked (91).
In addition to its a—adrenergic antagonistic properties, PhB also irreversibly antagonises
the intracellular protein calmodulin (CaM) (148). CaM integrates the vasoconstrictor-
mediated increasesin intracellular calcium to activation of the myosin light chain kinase
(MLCK),resulting in smooth muscle contraction (149). In previous work we foundthat
PhB had noeffect on the contractile response to ET 1, angiotensin II, vasopressin and
the depolarisation induced by KCI (92). These results suggest that any interaction with
CaMis unlikely to contribute to the antispasmodic action of PhB. Therefore PhB should
not be usedasthe sole agent in the prevention of RA spasm. Taggart’s group have since
have also recommendedthis (150).
Oneofthe concerns with the use of PhB is the possibility of an over expression ofnewly
formed a adrenoceptors owing to up-regulation. This has been shownto occurinrat
aorta smooth musclecells that have been treated with PhB and then incubated in the
presenceofangiotensin II. This could be very important clinically as levels of
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angiotensin II are raised postoperatively (151). The RA could become moresensitive to
catecholamines, making spasm morelikely.
Another problem with PhBis that there is an increased contractile response to
angiotensin II in PhB treated arteries (146). The AT) and the a—adrenoceptor are both
G-protein linked and may share componentsofintracellular calcium signalling (152).
PhB pre-treatment may therefore contribute to vasospasm ifit is mediated by non-
catecholamine factors.
1.6.5 Other Treatments
Dobutamineis a B)-receptor agonist, with B2- and a)-adrenoceptor agonist properties. It
is frequently used following cardiac surgery because ofits positively inotropic
properties. Its vasodilator properties are due to an increase in cAMP in smooth muscle
through activation of adenylyl cyclase and possibly the B—adrenergic pathway of
relaxation such asactivation of Ca**-sensitive potassium channels (136). Crawcoski et
al. have showed that dobutamine is capable of relaxing IMA and GEAringsin vitro but
wasnotas effective as sodium nitroprusside (133). Also at therapeutic levels it only
caused between 0 and 25% relaxation (133). Dobutaminealoneis therefore not a useful
vasodilatorclinically. However its action is potentiated by the phosphodiesterase
inhibitors enoximoneand milrinone (153) and a combination of drugs may be of some
use clinically.
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Potassium channel openers (KCO)are another drug of potential therapeutic value in the
prevention of spasm in the RA. He and Yang have shownthat the KCO aprikalim
caused relaxation of the human IMA to KCl, U46619 and phenylephrine (154). Pre-
treatment caused a decrease in the maximal responseto phenylephrine but not to KCI or
U46619, and shifted the concentration response curvesofall three compoundsto the
right (154).
Various vasoactive substances are produced,released or altered following cardiac
surgery. These substances include catecholamines, angiotensin II, thromboxane Az, ET
I, vasopressin, leukotrienes LTB4, LTC4, LTD4 and 5-HT (91). Manyofthese
substances could cause spasm of the RA. Manyinhibitors have been shownto prevent
contraction of the RA to specific vasoactive substance(see table 1.5).
Asit is not known which vasoconstrictor(s) are responsible for spasm in the
postoperative periodit is not possible to develop a strategy to prevent spasm bytargeting
a specific receptor. A more logical approach is to use drugs which block the pathways
that lead to contraction of vascular smooth muscle or cause relaxation ofit.
4]
  
Vasoconstrictor Inhibitor Site of Action Authors
Endothelin 1 BQ123 Endothelin A (845112)
receptor
AngiotensinII GR117289C AT} receptor (155;156)
Thromboxane Az GR32191B TP receptor (156)
Vasopressin SR49059 V1 receptor (155-157)     
Table 1.5 — Inhibition of Contraction of the Radial Artery Due To
Specific Vasoactive Substances
Batchelor et al. have shown in the IMAthat the rho-kinase inhibitors HA1077 and
Y27632 completely reverse sub maximal contractions of the thromboxane Az mimetic
U46619 and ET 1 (158).
Ascorbic acid (vitamin C) is the main water soluble anti-oxidant in human plasma(159).
It has been shownto reverse endothelial dysfunction in patients with ischaemic heart
disease (160). This has been attributed to an enhanced synthesis or the prevention ofthe
breakdownofnitric oxide (161). Drossos et al. have shown that vitamin C wasa potent
vasodilator of the RA in vivo andits effects were superior to diltiazem in patients with
coronary artery disease (162). However Mangoushet al. found that ascorbic acid was
only effective at preserving endothelium function after 72 hours incubation (163). This
incubation periodis not possible in the treatment of the RA priorto grafting.
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Genetherapy offers a potential way of preventing spasm. This technique involves the
use of an adenovirusto transduce the gene encoding for endothelial nitric oxide
synthase. Cable et al. report RA rings undergoing transduction of this gene showed a
significantly decreased contraction to KC] and to Prostaglandin F2,, (56). This
technique mayalso be used for the transfer of dominant negative constructs of Rho-A or
Rho-kinase.
1.7 Areas of work to be investigated
1.7.1 Mechanisms of spasm
The cause of spasm is unknown,butis likely to be multi-factorial (158). Trauma
following surgery, endothelial disruption, the presence of raised levels of
vasoconstrictors following surgery (164) and temperature changes (90) are all possible
causes. However spasm may occur many weeksor months following surgery when one
would have expected any effects of surgery to have disappeared andlevels of circulating
vasoconstrictors to have returned to normal. Also, these raised levels of circulating
vasoconstrictors are not high enough to cause contraction ofRA ringsin vitro.
Elucidation of the possible mechanisms involved in spasm will aid in the design of
successful strategies to preventit.
Plasma NAlevels are raised in the postoperative period from basal levels of 1.2-3.0 nM
to levels of 6-15nM (165). Since sympathetic nerve endings release NA in close
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proximity to the vascular smooth muscle of the arterial wall, interstitial concentrations
are likely to be much higher than those measured in the plasma. Interstitial NA is
difficult to quantify but the measured ECs9 for NA mediated contraction in RA rings
ranges from 0.04-0.7M. This suggests thatit is interstitial levels ofNA rather than
plasma concentrations that determine contractility.
It has been shownin saphenousvein grafts that after a week there is a decreased
response to tyramine, an agonist that displaces NA from nerve endings, and a decrease
in NA content (166). This suggests nerve endings have degenerated and therefore in-
vivo would, during that degeneration, have the potential to degranulate and cause spasm.
Whenvein grafts are placed underarterial pressure, although the contractile responseat
one weekis decreased, the NA concentration response curvein vein grafts is shifted to
the left. This decrease in contractile response is thought to be due changesin structure
of the vessel wall. However,arterial grafts do not undergo the samestructural changes
that vein grafts do. The maximal contraction may therefore be preserved andifthe same
super-sensitisation (shift in the concentration response curveto the left) occurs, the RA
would be particularly prone to spasm if nerve endings degenerate releasing NA.
Thepossibility that decaying nerve endings in the vessel wall may have the potential to
causeraised local levels of vasoconstrictors and hence spasm of the RA will be
investigated.
This will be investigated this by adding tyramine to human RA ringsin vitro. Whether
tyramineacts directly on Radial Artery Smooth Muscle Cells (RASMC),or via the a-
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adrenoceptorwill be looked at. Finally, possible ways of depleting nerve endings ofNA
prior to grafting using clinically-applied chemical treatments will be investigated.
1.7.2 Regeneration of New a-Adrenoceptors
PhB bindsirreversibly to the a; adrenoceptor, the major adrenoceptor on the human RA
(76). The vascular smooth muscle must regenerate new receptors de novo, before the
response to NAis restored (167). The length of action of PhB persists for several days
(144). However in smooth muscle cells cultured in the presence of angiotensinII,
adrenoceptor regeneration occurs to levels beyondthat originally present (168).
Angiotensin II levels are raised following cardiopulmonary bypass (165), therefore there
may be an overshootin adrenoceptor regeneration in the RA ifit is pretreated with PhB
prior to grafting. PhB would therefore prevent spasm in the initial postoperative period
but then the RA would become moresensitive to catecholamines, and spasm occurlater.
To investigate whether there is an overshoot in adrenoceptor regeneration; RASMCs
will be cultured and treated with PhB. Concentration response curves will be obtained
from cultured cells over a period of five days to measure the regeneration of functional
adrenoceptors. These experiments will be repeated in the presence ofphysiological
levels of a range of vasoconstrictors including angiotensinII.
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If theseinitial studies show the anticipated overshoot, radioligand binding will be used
to quantify the expression of a-adrenoceptors. Finally, organ culture techniques will be
used to try and confirm the effects in the native artery.
1.7.3 Developmentof Alternative Treatments to PhB
PhBis a novel concept as it employs an irreversible treatmentlocalisedto the graft.
Howeverit deals only with the potential catecholamine component of spasm. Several
otherclinically approved drugsirreversibly target the coupling of receptor occupancy to
contraction and therefore have a potentially broader effect against a variety of
spasmogens. The effects of other clinically approvedirreversible antagonists in the
treatment of vasospasm will be studied by investigating their influence on contractility
in arterial rings.
Theactionsofthe inhibitors will be tested against vasopressin and angiotensinII.
Levels of both of these vasoconconstrictors are raised in the post-operative period (165).
Also normalised responsesto both angiotensin II and vasopressin in the RA are stronger
and moresensitive than in the IMA,and occurirrespective of the presence of
endothelium (94;169;170), therefore it is important to be able to attenuate these
responses. In addition, vasopressin-induced contraction in the RA is comparatively
resistant to milrinone and GTN,two of the most commonly used vasodilatorstrategies
(94). The inhibition of the vasopressin-induced contraction in RA grafts would also be
particularly advantageous for surgeons, since they may wishto use vasopressin to treat
hypotensionin the postoperative period (104;171).
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The twoclinically approved irreversible antagonists that will be investigated are
fluphenazine mustard and minoxidil sulphate. Fluphenazineis used clinically as an
antipsychotic drug for the treatment of schizophrenia and other psyschoses. Minoxidil
sulphate is used clinically to treat severe hypertension resistant to other drugs and hair
loss.
Calmodulin Antagonist
Fluphenazine mustard is a cell permeable, irreversible antagonist of CaM (172). Its
mechanismofactionis by directly binding to CaM. Manyintracellular Ca”*signals are
mediated by the ubiquitous calcium binding protein, CaM. Its functionis to regulate a
numberofpathways. These include cyclic nucleotide metabolism, ion transport, protein
phosphorylation/ dephosphorylation cascade, cytoskeleton function,cell proliferation
and G protein mediated signalling (173). Binding of Ca’* to CaM leadsto the activation
of several Ca**-dependent enzymesincluding MLCK, CaM-dependentprotein kinase
and calcineurin (173). Phosphorylation of myosin light chain by MLCKleadsto
interaction between actin and phosphorylated myosin light chain, activation of myosin
ATPase, and subsequently to smooth muscle contraction. Inhibition of the activation of
MLCKwill prevent vasoconstriction
Potassium Channel Opener
Minoxidil sulphate bindsirreversibly to the vascular ATP-sensitive K* channel (Kp
channel) (174). Karp exist in a wide range ofcells including endocrine cells, smooth
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muscle cells, cardiac muscle cells and skeletal muscle cells (175). KCO relax smooth
muscle byselectively increasing the membrane permeability to K. This repolarises or
hyperpolarises the membrane decreasing the opening probability of voltage gated L- and
T- type Ca”* channels and inhibiting action potential formation. In addition KCO may
accelerate the clearanceofintracellular free Ca”* via the Na‘/Ca”* exchange(176).
Potent vasodilatation with nicorandil, a combined KCO and NO donor, has been
reported against endothelin-mediated contraction in the RA (177). Pinacidil, which
shares a common binding site with minoxidil sulphate and nicorandil on the Karp
channel, has also demonstratedits ability to reverse phenylephrine-induced contraction
in human RA (178). Therefore the activation of Karp channels would be expected to
reverse membrane depolarisation, inhibit calcium influx across the plasma membrane
and relax the pre-contracted RA.
Rho-kinase Inhibitor
Finally the rho-kinase pathway(see figure 1.4) will be investigated as another common
pathwaythat could potentially be blocked to prevent spasm. The sustained phase of
vascular smooth muscle contraction is thought to involve Ca”* sensitization (179). Itis
believed to be this phase that initiates clinical vasospasm in cerebral arteries (180). The
major mechanism ofthe Ca”* sensitization of contraction is through the inhibition ofthe
smooth muscle myosin light chain phosphatase, resulting in increased myosin light chain
phosphorylation and smooth muscle contraction at a constantintracellular calcium level
(179). It has been recognised that the monomeric G protein Rho and its downstream
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Figure 1.4 - Simplified diagram showing regulation of rhoA/rho-
kinase activity. Stimulation of the vascular smooth musclecell
activates rhoA by guanine-nucleotide exchangefactors (GEFs),
whichfacilitate exchange of GDP for GTP, thus rendering rhoA
active; GTP-bound rhoAactivates rho-kinase. This phosphorylates
the myosin-binding subunit of MLCP,thusinactivating it. Myosin
light chain (MLC) phosphorylation is regulated by MLC kinase
(MLCK, which phosphorylates and activates MLC) and MLC
phosphatase (MLCP, which dephosphorylates and inhibits MLC).
MLC phosphorylation leads to increased contractile tone via
enhancedcross-bridging with actin.
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target Rho-kinase can participate in sustained vasoconstriction by phosphorylating and
inhibiting myosin binding (181). Rho-kinase has been proposed to playa variety of
vascular smooth muscle disorders including hypertension, coronary andcerebral
vasospasm (180;182;183).
In summary,theinitial aim ofthis thesis is to investigate whether decaying nerve
endings in the vessel wall may havethe potential to cause raised local levels of
vasoconstrictors and hence spasm of the RA. Next the safety of the currently used
irreversible a-adrenergic antagonist, PhB, will be studied. This will be examined with
respect to whether there is an overshoot in a-adrenoceptor responses following PhB
treatment. Finally, the efficacy of an irreversible KCO,an irreversible CaM antagonist
and a rho-kinase inhibitor will be investigated.
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Chapter 2
Methods and Materials
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Ethical committee approval for the project was obtained from the Liverpool Research
Ethics Committee (ref 02/06/094/A) and the Cardiothoracic Centre, Liverpool NHS
Trust Research and Development Committee. Samples of RA, surplus to requirement
for CABG,werecollected at the Cardiothoracic Centre, Liverpool, with fully informed
patient consent.
2.1 Radial Artery Harvest Techniques
The RA washarvested with surrounding fat and the twosatellite veins using diathermy
and titanium surgiclips to achieve haemostasis on the RA in 74 patients, and surgiclips
only in 15 patients (see figure 2.1). Depending on the practice ofthe surgeons
concerned,radial arteries weretreated in the theatre with either 1.6 mM papaverine
(Martindale Pharmaceuticals, Romford, UK) or 6 mM PhB (Goldshield Pharmaceuticals
Ltd., Croydon, UK)in a solution of the patients’ whole blood containing 100 i.u.
heparin/ml for 30 minutes. Arterial sections surplus to surgical requirements were
collected from theatre into Dulbecco’s Modified Eagle Media (DMEM)(Invitrogen,UK)
on ice and immediately transported to the research laboratories.
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Figure 2.1 — Photograph showing harvesting of the RA with
surroundingfat and satellite veins (patients consent obtained)
2.2 Patient Details
RA samples were collected from 89 patients. The clinical characteristics ofthese
patients are given in table 2.1. In 40 patients, distal segments ofRA werecollected and
in 49, proximal segments. 44 radial arteries were pre-treated with 6 mM PhB and 45
with 1.6 mM papaverine.
ae
 Total numberofPatients 89
 
 
  
Meanage(years) 64
Sex ratio (Male: Female) 65:14
Risk Factors (n)
Current Smokers is
Ex-smokers 49
Non-smokers 27
Hypertension 50
Diabetes mellitus 23
Peripheral Vascular disease 12
Previous CVA or TIA 7
Preoperative Medication (n)
B blockers 70
Calcium channel blockers 44
ACEinhibitors 31
Nitrates 49
Potassium channel openers 28 
Table 2.1 - Patient Characteristics
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2.3 Materials
All tissue culture reagents were purchased from Invitrogen Ltd (Paisley, UK) andplastic
ware wasobtained from Sarstedt (Leicester UK). Reagents were purchased from DBL
(Warwick UK), Martindale Pharmaceuticals (Romford, UK), Goldshield
Pharmaceuticals Ltd (Croyton, UK), Abbott Pharmaceuticals Ltd (Maidenhead, UK),
Sigma Chemicals (Poole, UK) , Merck Ltd (Nottingham, UK), Molecular Probes
(Oregan, USA), Novacastra Laboratories (Newcastle-Upon-Tyne, UK) and Calbiochem
(Nottingham,UK)(Seetable 2.2).
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Chemical Company
Angiotensin II Sigma Chemicals
arg-vasopressin Sigma Chemicals
Bovine Serum Albumin Sigma Chemicals
CaCl2 Sigma Chemicals
D-glucose Sigma Chemicals
DMEM Invitrogen
Endothelin I Sigma Chemicals
fluo 4 Molecular probes
Foetal bovine Serum Sigma Chemicals
Glucose Sigma Chemicals
Goat anti-mouse IgG FITC labelled
secondary antibodies Sigma Chemicals
Glyceryltrinitrate DBL
KCl Sigma Chemicals
L-Glutamine Sigma Chemicals
MgSO, Sigma Chemicals
Minoxidil sulphate Merck
 
Mouseanti-human a smooth muscle
actin antibodies Novacastra Laboratories
 
Na,HPO, Sigma Chemicals
NaCl Sigma Chemicals
NaHCO; Sigma Chemicals
Noradrenaline Abbott Pharmaceuticals Ltd
Papaverine Martindale Pharmaceuticals
Phenoxybenzamine Goldshield Pharmaceuticals Ltd
Pluronic F-127 Sigma Chemicals
Polyclonal rabbit IgG against S100 Dako
protein
Reserpine Merck
Sodium Bicarbonate Sigma Chemicals
Sulphinpyrazone Sigma Chemicals
Tyramine Sigma Chemicals
Y27632 Merck  
Table 2.2 - Reagents Used
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2.4 Culture ofHuman Radial Artery Smooth Muscle Cells
RASMCwere grownfrom explants using a method basedonthat described by
Kirschenlohr e¢al. (184). Small sections of RA (0.5-3.0cm), surplus to CABG, were
obtained with informed patient consent. They were then transferred to the tissue culture
laboratory in ice cold DMEMcontaining antibiotic (100U/mlpenicillin, 100pg/ml
streptomycin sulphate and 0.25y.g/ml amphotericin B). The artery was opened
longitudinally and the endothelium scrapedoff using sterile scalpel. If visible, the
intima waslifted off using a pair of watchmakers’ forceps. The tunica-media containing
the smooth muscle was then removed and gently chopped, using scissors, into pieces of
1-2mm. These pieces were re-suspended in culture medium (DMEMcontaining 4mM L-
glutamine, 2.5mM glucose and 4.5mM sodium bicarbonate) supplemented with 20%
foetal bovine serum (FBS) andantibiotic (100U/mlpenicillin, 100p1g/ml streptomycin
sulphate and 0.25ug/ml amphotericin B), and transferred to 25cm’tissue cultureflasks.
The pieces were spread evenly over the bottom of the flask and the medium aspirated
leaving only a thin film, sufficient to keep the tissue moist. The flask wasleft in a
humidified tissue culture incubator at 37°C for a minimum of 2 hoursto allow the pieces
to adhere. After this time 1.2mls of culture medium wasadded. After 3 days any
unattached tissue was removed and the media changed. Thereafter media was changed3
times a week. Whenconfluent, explant pieces were gently floated off in an excess of
media andthecells allowed to recover for 2 days before subculturing. RASMC were
detached using trypsin/EDTA solution and reseeded into a 75cm? flask. When confluent
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the RASMCwerethenfurther passaged into three further 75cm?flasks or onto a 96 well
plate for imaging. Cells were routinely used within the first four passages.
2.5. Antibody Staining ofHuman Radial Artery Smooth Muscle
Cells
Smooth Muscle cells were cultured to confluency on glass coverslips and fixed with 4%
paraformaldehyde in phosphate buffered saline (PBS). Fixed cells were then treated
with 50mM NH,Clfor 10 minutes and then permeabilised with 0.1% Triton X-100 for
10 minutes. Coverslips were then incubated with mouseanti-human a smooth muscle .
actin antibodies (Novacastra Laboratories, Newcastle-Upon-Tyne, UK)at 1:50 dilution
overnight in the presence of 1% bovine serum albumin (BSA) and then incubated with
goat anti-mouse IgG (Fab specific) flourescein isothiocyanate (FITC) labelled secondary
antibodies (Sigma, Poole, UK), at 1:500 dilution overnight in the presence of 1% BSA.
Following washing cover slips were mounted on microscopeslides using Gelvatol
Airvol mountant and positive staining was visualised using a x60 objective of LEITZ
Diaplan fluorescence microscope (Leitz-Wetzlar, Wetzlar, Germany) housed in the
Department of Anatomyand Cell Biology, University of Liverpool, using standard FITC
filters. Negative controls where control mouse serum wasusedin place of the primary
antibody were included to confirm positive staining.
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2.6 Calcium Imaging
Radial artery smooth muscle cells were cultured to confluence on five 96 well plates
(Sarstedt, Inc. Leicester UK). All plates were fed 3 times a week and always on the day
prior to imaging. All calcium imaging was performed in HEPES-Buffered Saline (HBS)
composed of: HEPES, 20mM;NaCl, 145mM; D-glucose, 10mM; CaCl2, 1mM ; pH 7.4
at 37°C.
Initially the cells were placed on serum free culture media for at least 48 hourspriorto
commencing the experiment to maintain a quiescent phenotype. Howeverthe cells had
a tendency to lift on serum free media even in the presence of 0.1% BSA. Results
obtained from cells placed on serum free media for 48 hours, and cells not placed on
serum free media were identical for the initial experiment where « adrenoceptor
regeneration wasinvestigated notin the presence of any vasoconstrictor, therefore all
further experiments were performed withoutplacing the cells on serum free media for 48
hours prior to the commencementofthe experiment.
Vasoconstrictor-induced changesin intracellular calcium concentration were recorded in
RASMCloaded with the calcium sensitive fluorescent dye, fluo 4. Cells were loaded
with 2uM fluo 4 (Molecular Probes, OR, USA), 0.025% ofthe detergent Pluronic F-127
at 37°C for 120 min, in 1001 loading buffer consisting ofHBS plus sulphinpyrazone,
200M,to prevent dye leakage, and 1 % BSA.After loading, extracellular dye was
aspirated andthe cells maintained in 50,11 dye-free HBS. Agonist stimulated changesin
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intracellular calcium were monitored using a Wallac ‘Victor’ 1420 Multilabel counter
(Perkin-Elmer, UK). A single row (12 wells) was imagedat a time. Cells were then
excited at 490nm andthe resulting fluorescence monitored at 520nm. Then 501 of
agonist was added to each well and the fluorescence measurement repeated. The change
in fluorescence wascalculated by subtracting the meanofthe first reading from the
meanofthe second reading. Once this was complete the dispenser wasflushed with the
next agonist and the process repeated for the next row of the 96 well plate.
It was noted that during the course of imaginga plate there was a gradual increase in
background fluorescence. The explanation for this was thought to be dye leakage. To
confirm this, the experiment was repeated with 1mM manganese chloride being added to
the well, to quench any extracellular dye, just prior to the initial fluorescence reading on
each row.
The experiments were also repeated, but instead of the addition of an agonist to each
row, buffer was added to each row to assess the effect of dye leakage on the change in
fluorescence. All other aspects of the experiment were kept the same including flushing
of the dispenser to keep the time period of the experiment the same. This allowed a
value to be calculated for the contribution of dye leakage to change in fluorescence of
each row with time.
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2.7. Organ Bath Techniques
Organ bath contraction studies were carried out at 37°C in oxygenated Krebssolution
composed of; NaCl, 118 mM; KCl, 4.7 mM; NagHPOg, 1.2 mM; MgSO, 1.2mM;D-
glucose, 10 mM; CaCl, 1mM; NaHCO; 25mM.
2.7.1 Pre-tensioning of Rings
Various methodsofpre-tensioning vascular rings have been described. These methods
are based aroundvariations oftwo separate methodsinitially described by Mulvany and
Halpern (185) and Cohen (186).
Weadopted a method, based on that described by Mulvany, similar to that used by He
and Yang (170;176;187-193) and that we had used in previous studies (92). The length
of time rings were stretched and relaxed prior to use was decreased from 30 minutes to
20 minutesin orderto aid in the processing ofmore than one sample per day. This
decrease in time appeared to have no effect on the maximaltension pulled bythering.
Maximaltensions pulled after 20 minutes and 30 minutes were 9.87g+0.43 vs.
9.12g+0.44 respectively (p=0.25) (See figure 2.2).
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Figure 2.2 — Bar chart showing maximaltension pulled in response
to 90mM KCI by proximal RArings, pre-tensioned for 20 minutes and
30 minutes respectively. Bars represent mean +SEM.
Samples of artery were trimmed of connective tissue and cut into 2-3mm rings using a
scalpel. Prior to mounting in the organ bath, a ring wasselected at random and divided
along its length. The length of this strip of artery was then measured with a micrometer
to give the relaxed internal circumference. The remaining rings were mounted in 25mls
Krebs solution between twofine wire stirrups connected to a force transducer and
changesin isometric force were recorded on a PowerLab 16SP data recording system
connected to an Octal ML119 bridge amplifier (AD Instruments Ltd, Chalgrove,
Oxfordshire, UK) (See figure 2.3). Each ring wasstretched to a tension equivalent to
100mmHgandthetension allowed to decline for 20 minutes, after which it was
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readjusted again to a similar tension and allowedto decline for a further 20 minutes.
Following this the tension was relaxed to approximately 90% of their maximal
circumference for a further 20minprior to the addition of agonists.
 
Figure 2.3 — Organ bath and recording system
The wall pressure of the RA ring wascalculated from the following equations.
Wall Tension per unit area — T
Vessel length — g
Force exerted by vessel on force transducer — F
Transmural pressure — P
Internal Circumference — L , Lp — relaxed , L, — stretched
Stretch — §
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T=F/2g
P=2nT/L
L,=Lpt+2s
Wehave madethe following assumptions:
1. The ring is a thin walled tube.
2. T is unaffected by the curvature caused by suspensionofthe ring in the organ
bath.
Details of individual organ bath experimentare given in the relevant chapter.
2.8. Regeneration of Radial Arteries in Organ Culture
Distal sections ofRA pre-treated for 30 minutes with 6mM PhB werecollected from
theatre. This has been shownto abolish the NA-mediated contraction (193). The RA
wascut into 6 rings 2-3mm in length. Oneofthe rings was mounted in the organ bath as
described below and responses to 90mM KCl, increasing concentrations ofNA (0.1M,
1uM, 2uM, 4uM, 10 uM and 100 uM), and 100nM vasopressin recorded. The other 5
rings were placed under 6g of tension, provided by an external weight, in a petri dish
with DMEM (with 4mM L-glutamine, 2.5mM glucose and 4.5mM sodium bicarbonate)
containing 20% FBSand antibiotic. The petri dish was then placed in the tissue culture
incubator. At 24 hourintervals a ring was removedand the organ bath experiment
repeated. The media was changed every 24 hours.
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2.9 Statistical Analysis
Analyses were carried out using the programs Arcus QuickStat Biomedical (Hearne
Scientific Software, Dublin, Eire).or Graphpad Prism version 3.02 (Graphpad Software,
California, USA).
In chapters 3 and 4 data is expressed as meanplus or minus standard error ofthe mean
(SEM). In chapter 5 data is presented as mean + standard deviation of the mean (SD),
which wasthe preferred method by the journal in which this chapter was published.
Ap valueofless than 0.05 was consideredstatistically significant. n refers to the
numberof independent samples tested
Comparison between two groups were madeusinga paired 2 tailed student’st test A
one way analysis of variance (ANOVA)and a Bonferroni correction was used for
multiple group comparisons.
Concentration response curve were constructed and ECs calculated using non-linear
regression methods on Graphpad Prism. This was used to calculate ECso.values. They
are expressed as mean (with 95% confidence intervals). ECso.values are compared
using a one way ANOVA.
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Chapter 3
Degenerating Nerve Endingsin the Wall of the Human
Radial Artery May cause Spasm
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3.1. Introduction
Whenvein grafts are placed underarterial pressure, although the contractile responseat
one weekis decreased, the NA concentration response curve in vein grafts is shifted to
the left (194). This decrease in contractile response is thought to be due to changes in
the structure of the vessel wall. However,arterial grafts do not undergo the same
structural changes that vein grafts do. The maximal contraction may therefore be
preserved, and if the same super-sensitisation occurs, the RA would be particularly
prone to spasm if nerve endings degenerate releasing NA. Consequently sympathetic
nerve endings maybea potential source of spasmogenic NA.
Theaim ofthis workis to investigate the possibility that degenerating nerve endingsin
the vessel wall of the RA havethe potential to cause contraction of the RA. If this is a
possibility, then methodsofpreventing this will be investigated
The presence of sympathetic nerve endings in sections ofhuman RA will be confirmed
by staining for S100 protein. The response of RA rings to tyramine will then be tested
in the organ bath. To confirm that any response is mediated by the a-adrenoceptor, PhB
will be used to try and block the response. Tyramine will then be added to cultured
RASMCto see whetherit exerts a direct response on the cells or whetherit is acting via
another method. Finally, various chemical treatments will be investigated to determine
waysnerve endings could be depleted of NApriorto grafting.
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The drugs that we will use to try and deplete nerve endings are guanethidine
monosulphate, reserpine and 6 hydroxy-dopamine. Guanethidineis a drug which is used
clinically to treat a hypertensive crisis (195). Guanethidineis taken up into the
noradrenergic nerve terminal by the uptake 1 system. Once insideit blocks the release
ofNA in responseto an action potential.
Reserpineis a centrally acting anti-hypertensive. It is available in the USA but no
longerusedclinically in the UK. It is an alkaloid that comes from the shrub, Rauwolfia.
It acts by blocking the transport of NA into the synaptic vesicles. The NA accumulates
in the cytoplasm whereit is broken down by monoamine oxidases (MAO). The NA
content of the tissue drops and synaptic transmission is blocked.
6 hydroxy-dopamineis similar in structure to dopamine exceptthat it possess an extra
hydroxyl group. It is taken actively up by noradrenergic nerve terminals, whereit is
converted to a reactive quinine, which destroys the nerve terminal. It is available in this
country for experimentaluse only.
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3.2 Methods and Materials
Samples ofRA were obtained from patients undergoing CABG.They were harvested as
described in chapter 2. 49 rings from 27 patients were usedintotal.
3.2.1 S100 stain
6 RA rings from 3 patients were used. RA segments were embeddedin paraffin wax.
From each block 5m sections were cut. Sections were washed overnight with 0.01M
phosphate-buffered saline containing 0.5% Triton X-100. After washing with PBS,the
specimensweretreated with the same buffer that contained 0.3 % H202, and washed
with PBS again. They were incubated for 1 hour with non-immune 2% goat serum. The
specimenswerethen incubated with polyclonal rabbit IgG against S-100 protein (Dako,
Ely UK)at 1:1000 dilution, overnight at 4°C. After the incubation, samples were treated
with biotinylated antibody against rabbit IgG raised in 0.5% goat serum (Vector,
Peterborough, UK), for 1 hour at room temperature. Immunoreactive sites were
visualised by incubation with Tris-HCl buffer that contained 3,3'-diaminobenzidine
tetrahydrochloride and H202. Immunostained specimens were mounted onslides coated
with chrome alum andgelatin, air-dried, dehydrated in an ethanol series, cleared with
xylene, and sealed under coverslips.
For immunohistochemical controls, normal rabbit IgG was used instead of polyclonal
rabbit IgGs against S-100 protein. Additional sections were stained with haematoxylin
and eosin.
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3.2.2 Organ Bath Experiments
Proximal RA samples were used for these organ bath experiments. They had beenpre-
treated in theatre with 1.6mM papaverine. RA rings were set up and pre-tensioned in
the organ bath as described in chapter 2. All rings wereinitially contracted with 90mM
KCIto test for functional contractility. Responses were terminated by washing with
three complete changes ofmedia. 7 rings from 3 patients were stimulated with
increasing concentrations of tyramine to construct a concentration response curve.
The effect of PhB on tyramine induced contraction wasinvestigated using 14 rings from
5 patients. In order to block any a adrenergic responsehalf of the rings were treated
with 0.1mM PhBfor 30 minutes and half left untreated. Following washout, tyramine
500uM wasthen addedtoall the rings andthe strength of contraction noted. Any
contraction was then reversed by increasing concentrations of GTN.
To investigate tyramine-induced tachyphylaxis, 500uM tyramine wasthen addedto all
the rings andthe strength of contraction noted. The response was washedout and the
tension allowed to return to basal levels. Rings were then stimulated with 100.M NAto
check that any failure to respond to the second addition of 500uM tyramine was due to
depletion ofNA in the nerve endings and not receptor desensitisation.
Finally, 100nM vasopressin wasaddedto the rings to confirm theystill contracted.
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To determine whether RA rings had the potential to replenish NA following depletion
with tyramine, rings were initially treated with tyramine, washed out and then 100uM
NAwasadded. Followingthis a further dose of 500uM tyramine was addedto see if the
rings respondedto this second dose of tyramine following exposure to high
concentrations ofNA.
To investigate the effects of guanethidine, reserpine and 6 hydroxy-dopamineon the
tyramine response, a further set of experiments werecarried out using 14 rings (1
discarded) from 3 patients. The rings were either pre-treated with guanethidine,
reserpine or 6 hydroxy-dopamine for 15 minutes and the response to 500).M tyramine
recorded
3.2.3 Calcium Imaging
RASMCwerecultured to confluency on 96 well plates as described in chapter 2. Cells
were washed with HBSandthecells loaded with the calcium sensitive dye Fluo 4 ina
total volume of 100,11 of loading media per well which contained 2M Fluo 4, 200uM
sulphinpyrizone (SPZN), 0.025% F127, 1% BSA. Cells were loaded for 2 hoursat
37°C. Followingthis, the loading media wasaspirated and 50u1 ofbuffer placed in each
well. Cells were excited at 490nm and changesin fluorescence monitored at 525nm
using a Wallac ‘Victor’ 1420 Multilabel counter (Perkin-Elmer, UK)
The background fluorescence was measuredin thefirst row of 12 wells (5 readings per
well). Following this 50u1 ofbuffer was added to each of these wells and the peak
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changein fluorescence measured (5 readings per well). This was repeated for rows 2 to
4 with the addition of 50u11 of ImM tyramine, 200uM NAor 200nM angiotensin II
respectively.
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3.3 Results
3.3.1 S100 antibody staining
Immunohistochemistry on 6 rings from 3 patients with S100 antibody confirmed the
presence of nerve endingsin all sections (see figure 3.1).
 
Figure 3.1 — Medium power microscopy showing nerve endingsin
RA sections stained with polyclonal rabbit IgG against S-100 protein
(—~>)
73
3.3.2 Organ Bath Experiments
Patient characteristics are shown in table 3.1.
 
 
 
  
Total numberofPatients 11
Meanage(years) 61
Sex ratio (Male:Female) 9:2
Risk Factors (n)
Current Smokers 3
Ex-smokers 6
Non-smokers 2
Hypertension 7
Diabetes mellitus 3
Peripheral Vascular disease 1
Previous CVA or TIA 0
Preoperative Medication (n)
B blockers 8
Calcium channel blockers 5
ACEinhibitors 4
Nitrates 8
Potassium channel openers 2 
Table 3.1 — Patient characteristics
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A concentration response curve for tyramine was constructed (see figure 3.2). The ECs
was 272+33uM. A concentration of 500uM tyramine wastherefore used for the rest of
the experiments in this chapter to achieve a maximalcontraction.
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Figure 3.2 - Tyramine concentration response curve. Increasing
concentrations of tyramine were addedto 7 rings from 3 patients.
Responsesare shownasa percentage of maximal responseto
tyramine. Mean valuesfor each doseare plotted. Error bars
represent SEM.
Using 14 rings from 5 patients the effects of PhB on tyramine-induced contraction were
compared. Half of the rings were treated with 0.1mM PhBandhalfleft untreated. All
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rings responded to 90mM KCI. The meanforce of contraction was 3.97+40.40gin the
untreated group and 4.10+0.57g in the PhBtreated group (figure 3.3). There was no
significant difference between the PhB and untreated rings. (p=0.76).
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Figure 3.3 — Responseof PhBtreated and untreated rings to
tyramine. Representative organ bath traces from individual rings of
human RA showinganinitial response to 90mM KCI. 0.1mM PhB
was addedto ring B for 30 minutes then washed out. 500uM
tyramine was addedto both rings. Following washout 100nM
vasopressin was addedto therings.
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All the rings in the untreated group showeda significant increase in tension in the
presence of 500uM tyramine 2.76+0.40g, 64.5+8.7% of the 90mM KCIresponse(figure
3.4). This did not occur in the presence of PhB (p<0.0005). To confirm functional
contractility at the end of the experiment,all rings responded to 100nM vasopressin at
the end of the experiment. There wasnostatistical difference between the untreated and
PhB treated rings 4.31+0.87g; 102.14+12.87 %KCIvs. 3.94+0.70g; 92.8048.57 %KCl
response (p=0.51) (Figure 3.4).
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Figure 3.4 -Comparison of Tyramine and Vasopressin responsesin
PhBtreated and untreated rings. Responses are expressed as a
percentageof theinitial 90mM KCl response. Bars represent mean
+SEM. * denotessignificant difference versus control (p<0.0005)
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The response wasreversed by increasing concentrations of GTN (Figure 3.5) however
relatively high concentrations were necessary to completely reverse the contraction.
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Figure 3.5 — Relaxation of tyramine induced contractionsin the
humanRAbyincreasing concentrations of GIN. Values are
expressed as a percentageof the tyramine induced contraction.
Bars represent mean +SEM.
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Totest for tyramine-induced tachyphylaxis, following a washout, a further 500M of
tyramine wasthen addedtoall the rings and the strength of contraction noted. This did
not cause an increase in tension in anyofthe rings tested. However,after thisall rings
responded to 100uM NAfollowing washout giving a response,not significantly
different from the response to tyramine 71.42+5.2 %KCI vs. 85.7+7.01 %KCI(figure
  
   
  
3.6 and 3.7).
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Figure 3.6 — Representitive organ bath trace showing comparison of
responses to 90mM KCI, 500uM tyramine and 100uM noradrenaline
in a humanradial artery ring. Each response wasreversed by 3
complete changesof media.
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Figure 3.7 — Comparison of maximal 500 pM tyramine and
100M noradrenaline responses. Responsesare expressed as a
percentage of the maximal 90mM KCI response. Bars represent
mean +SEM.
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In experiments designed to deplete nerve endings ofNA by chemicaltreatment, sections
ofRA from each patient waspre-treated with either 54M reserpine, 1mM guanethidine
or 2mM 6-OH dopaminefor 15 minutesprior to stimulation with tyramine. These
drugs were washedoffby 3 complete changes of mediaprior to the addition oftyramine.
The responsesare shownin figure 3.8. Reserpine significantly decreased the contractile
response to tyramine (p<0.05).
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Figure 3.8 — Tyramine responses in humanradialartery rings; in
controls and in rings treated for 15 minutes with either 5uM
reserpine, 1mM guanethidine or 2mM 6-OH dopamine. Responses
are expressed as a percentageof the initial 90mM KCI response.
Bars represent mean +SEM. * denotessignificant difference versus
control (p=0.013). n=13 rings from 3 patients.
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3.3.3 Calcium Imaging
To confirm that tyramine wasnot an agonist at the a-adrenoceptors present on the
RASMC,cultured RASMC loaded with the calcium sensitive dye Fluo 4 were
stimulated with tyramine and responses compared with NA. Thetotal change in
fluorescence was measured over 30 seconds to determinethe net effect on calcium.
There wasnosignificant increase in calcium fluorescence on addition of 1mM
tyramine compared with the addition ofbuffer (p=0.3014). However there was a
significant increase in fluorescence on addition of 200HM NA(p<0.01) and 200nM
angiotensin II (p<0.01) (see figure 3.9).
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Figure 3.9 - Lack of Stimulation of RASMC’s with tyramine. Bar
chart showing increase in fluorescence on addition of buffer, 1mM
tyramine, 20uM noradrenaline and 200nM angiotensin Il. Bars
represent mean +SEM. * denotessignificant increasein
fluorescence.
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3.4 Discussion
Vasospasm is easy to explain in the immediate post-operative period following
surgical trauma and whenraised levels of vasoconstrictors are present. However,
spasm may occur many weeks following surgery (34;40;49;57;58;196) when one
would have expected any effects of surgery to have disappeared andlevels of
circulating vasoconstrictors to have returned to normal.
It has been demonstrated in saphenousvein grafts that there is a decreased response
to tyramine one week following implantation and there is a decrease in NA content
(166). It has been suggested that these results are due to denervation The concept
of denervation is further supported by the lack of responsivenessofvein grafts to
electrical stimulation (194). There is no reason to suggest that a similar process does
not occur in the RA. With its greater smooth muscle content when comparedto the
saphenousvein (197), increased contractility (198) and its increased sensitivity to
catecholamines the RA would be moreproneto contraction stimulated by the release
ofNA from degenerating nerve endings.
Weinvestigated the hypothesis that the degeneration of nerve endings in the vessel
wall could potentially release significant amounts ofNA and hence cause spasm.
Tyramine,a naturally occurring monoaminegets taken up into the nerve terminal via
Uptake 1 (the neuronal reuptake system for NA) and then displaces NA from the
storage vesicles, allowingit to leave the nerve terminal and stimulate the
adrenoceptors. Addition of tyramine to human RA ringscauseda significant
increase in tension in all rings tested that was equivalent to a maximum concentration
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NAresponse. This effect was blocked by pre-treatment with the irreversible
a adrenergic antagonist PhB, demonstrating that the response to tyramine was
mediated by the « adrenoceptors present on the smooth muscle. Howevertyramine
itself did not causea rise in intracellular calcium in cultured RASMC demonstrating
that it was not tyramine itself that caused the contraction. This suggests that nerve
endings in the vessel wall have the potential to release significant local
concentrations ofNA to cause an increase in tension of the RA ring. This is similar
to that seen by others in the saphenousvein (166).
After relaxation with GTN and washingoffthe GTN,the rings failed to respond to a
second dose of tyramine. Thefailure of a tissue to respond to a second addition of
tyramine is well described and termed tachyphylaxis. The exact mechanism of
tyramine tachyphylaxis is uncertain (199). The classical hypothesisis that tyramine
causes a rapid depletion ofNA and further administration oftyramine doesnotelicit
a responseas the NA contentofthe nerve endingsis no longersufficient to cause a
contraction (200). Various groups have shownthat tyramine only partially depletes
sometissues ofNA in vivo (199;201;202) andin vitro (199;203), while others have
shownthatit depletes the majority ofNA from nerve endings (204;205). Possible
explanations for these differences may be the presence of tyramineresistant pools of
NAin sometissuesor species, or the ability of various tissues to reuptake or
synthesise new NA. It has been demonstrated that tyramine tachyphylaxis could be
preventedin rat hearts by perfusing them with tyrosine, a precursor for NA (201).
Others claim a responsewill not occur if the NA content of the nerve ending has
been depleted by greater than 75% (202). After treating the rings with a high dose of
NA following tyramine administration we were then able to prevent tyramine
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induced tachyphylaxis. This is presumably because the nerve endingsare able to
reuptake the excess NA andreplenish their stores.
The possibility that the failure of the rings to respond to the second dose of tyramine
wasdueto desensitisation of the « adrenoceptors was excluded, asall the rings
respondedto stimulation with NA following tyramine addition and relaxation.
He and Yang have demonstrated that the RA has a dominance of a; adrenoceptor
function but post-junctional a, adrenoceptorsare present (76). Post-junctional a
adrenoceptors are composed of a; and a subtypes. The contribution ofa
adrenoceptor to drug induced contraction dependson particular blood vessels and
species, as well as the diameter ofthe blood vessel (206;207). In the human, RA
drug induced contraction is via both a; and a2 subtypes (76). It is unknown which
subtype of adrenoceptors mediate neuronal sympathetic vasoconstriction in the
human RA. Medgett and Langer (208) reported that «2 adrenoceptors do not mediate
neuronal sympathetic vasoconstriction in the cat middle cerebral artery as they are
located extra-junctionally. However, more recent reports have shownthat
postsynaptic a-adrenoceptors can be involved in the vasoconstrictor response to
sympathetic nerve stimulationto a significant (209) or even predominantlevel
(76;83). These experiments confirmed that the tyramine evoked contraction in the
RA is via « adrenoceptorsas it is blocked by the irreversible a adrenoreceptor
antagonist, PhB. Further work is needed to determine whetherthis responseis via
the a or a2 subtype of adrenoceptor.
It has been shownthat saphenousvein grafts show an altered vascular reactivity
(194;210). Solimanet al. have demonstrated that there is an enhancedsensitivity in
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grafted vessels to NA at a week following grafting, as the NA dose response curveis
shifted to the left (166). This enhancedsensitivity may be due to denervationasit is
seen in vein grafts that are placed in thearterial or venous systems (194). Despite
there being a super-sensitivity to NA in saphenousvein grafts, the maximal
contraction of grafted vessels to NA is reduced whengrafted in the arterial system
(166;194;210). This has also been shownin the saphenousvein following high
pressure distension (211). Morphological changes such as mechanical deformation
of vascular smooth muscle (212), and structural reorganisation of the contractile
elements within the vessel wall (213) could explain the reduced maximalcontraction.
This decrease in maximal contractility does not occur in the saphenous vein whenit
is grafted into the venous system. (194). The morphological changes seen in venous
grafts placed in the arterial system have not been demonstratedin arterial grafts in
the postoperative period, therefore the maximal contractile response in thesearteries
maynot be decreased, and in fact may be enhanced dueto the any super-sensitivity
present.
Degenerating nerve endings maybea potential cause of spasm in vivo, and would
explain why spasmisstill seen after levels of circulating vasoconstrictors have
returned to normal following surgery, and any effect of handling during the operation
resolved. It was shown in these experiments that PhB prevented contraction of the
RA due to tyramine evoked release of NA. A way of preventing spasm due to
degenerating nerve endings releasing NA forthe first 48 hours post-operatively is by
the topical application of PhB at the time of surgery (143). Howeverthere will be
regeneration of a receptors over the 48 hours following surgery and the effects of
PhB will notbe present after this time. Tyramine could be used to degranulate nerve
endingsat the time of surgery priorto grafting but we believe the nerve endings may
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reuptake NA,especially as circulating NA levels are raised in the post-operative
period (165), or synthesise more NAfor release at a later date makingthis
treatment ineffective.
Three possible drugs that could alter the release of NA from nerve endings,
reserpine, guanethidine and 6 hydroxydopamine,were investigated. Reserpine
inhibits the amine uptake process in the vesicle membraneandthereby allows
leakage ofNA into the cytoplasm whereit is broken down by neuronal MAO.
Furthermore, since vesicular dopamine uptakeis inhibited, NA synthesis is impaired.
NAdepletion is accelerated by action potential activity in the neurone.
Noradrenergic transmission fails when NA content is reduced to 25% of normal.
Whenlarge doses of reserpine are used, recovery of neuronal function depends on
synthesis ofnew vesicles and their transport to the axon terminals which takes
approximately 10 days. Guanethidine impairs transmission at the neuroeffector
junction
Of these drugs, reserpine abolished the response of the RA to tyramine. This is
similar to the effects of reserpine on the rat heart. One would expect the effects of
reserpineto last at least 10 days for reasons stated above; the effects may however be
permanentifthe nerves are no longer functional. 6-Hydroxydopaminefailed to
abolish the response of the RA to tyramine. This is not what was expected as 6-
hydroxydopamine worksin a similar way to reserpine. It may be that a higher
concentration or longer incubation period was required. Further experiments are
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needed to investigate this. Guanethidine failed to deplete the nerve endings ofNA.
This may well be due to the denervated nature of the nerve endings.
In conclusion nerve endingsin the wall ofthe RA havethe potential to degranulate
and cause contraction ofthe RA rings. This may be one of the mechanismsthat cause
spasm in the RA. Spasm could be prevented by destroying the NA vesicles with
reserpine at the time of operation prior to grafting, or degranulating them with
tyramine and reversing the contraction with GIN. A combination ofthe two
methods may be necessary.
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Chapter 4
Regeneration of c—Adrenoceptors
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4.1 Introduction
PhB has been recommendedto prevent spasm in RA conduits for CABG (150). PhB
bindsirreversibly to the a)-adrenoceptor, the major adrenoceptor on the human RA
(76). Consequently, the vascular smooth muscle must regenerate new receptors de
novo, before the response to NAis restored (167). The action of PhB persists for
several days (144), however, in smooth muscle cells cultured in the presence of
angiotensin II, adrenoceptor regeneration occurs to levels beyondthat originally
present (168).
The explanation for these findings could be due to the fact that angiotensinII plays a
role as a growth modulator in vascular smooth muscle (214). Angiotensin II has
been shownto increase vascular smooth muscle cell DNA synthesis in vivo and in
vitro (215-217). ACEinhibitors, which inhibit the formation of angiotensin II, have
been shownto prevent the development of neointimal hyperplasia after balloon
injury in the rat (218). Activation of protein kinase C leads to a marked induction of
the o-adrenoceptor gene (219). Angiotensin II is knownto activate protein kinase C
in vascular smooth muscle via the stimulation of phospholipase C (220).
Since angiotensin II levels are raised following cardiopulmonary bypass (165), there
may be an overshoot in adrenoceptor regeneration in the RA ifit is pre-treated with
PhBpriorto grafting. If receptor regeneration occurs and leadsto ‘sensitisation’ of
the artery PhB would therefore prevent spasm in theinitial postoperative period, but
then the RA would become moresensitive to catecholamines and henceproneto
spasm later.
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To demonstrate if this expected overshoot in adrenoceptorsensitivity occurs the
sensitivity of cultured RASMC [Ca’"], responses to NAstimulation will be
examinedafter a period of pre-treatment and recovery from PhB. RASMCwill be
grownonfive 96 well plates. Following treatmentofhalf of each plate with 11M
PhB for 1 hour(sufficient to completely block the a-adrenoceptors of the RA (144),
concentration response curves will be obtained from cultured cells over a period of
five days to measure the regeneration of functional adrenoceptors. The experiments
will be repeated with the cells incubated in the presence of angiotensin II, ET I,
vasopressin or NA after the treatment with PhB.
The experiments will then be repeated in an organ culture model to confirm the
results from cultured cells.
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4.2 Methods and Materials
4.2.1 Calcium Imaging
RASMCwere cultured as described in chapter 2. When confluent in a 75cm’tissue
culture flask they were reseeded onto five 96 well plates. The cells were grown on
the 96 well plates to confluence. Once confluent, rows 1-6 of all 5 of the plates were
treated with 14M PhB in DMEMcontaining antibiotics and 20% FBSfor 1 hourat
37°C. Rows7-12 werejust treated with the DMEM. After the hour the wells were
aspirated and culture media addedto four of the plates. The remaining plate was
loaded with fluo 4-AM dyeand calcium imaging carried out as described in chapter
2. The remaining four 96 well plates underwent media changedailytill imaged.
Oneplate was imaged on each of the following days. Three plates, from three
different cell lines were imaged for the day of treatment and the 4 subsequent days.
Parallel studies were also carried out with the cells incubated in the presence of
100nM angiotensin II, 100nM ET-1, 100nM vasopressin and 104M NAto measure
whether receptor regeneration is affected. Culture media was changed every 24 hours
to maintain levels of vasoconstrictors.
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The following additions were carried out
 
 
  
Row Addition
A Buffer
B 0.1u4M Noradrenaline
C 1M Noradrenaline
D 2uM Noradrenaline
E 4uM Noradrenaline
F 104M Noradrenaline
G 100M Noradrenaline
H 100nM Angiotensin II 
Each experiment was repeated with 3 different batchesof cells.
4.2.2
Distal segments of RA, pre-treated with 6mM PhBin theatre, were divided into rings
and used for experiments on that day (Day 0) or cultured as described in chapter2.
On consecutive days a RA ring was mounted in the organ bath and pre-tensioned as
described in chapter 2. Responses to 90mM KCl,increasing concentrations ofNA
(0.1u.M, 1uM, 2uM, 4uM, 10 uM and 100 uM)and 100nM vasopressin were
recorded. If the ring did not respond to KCI then another ring wasselected and the
Organ Culture Study
process repeated on the same day.
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4.3 Results
All cells were confirmed as being smooth muscle cells as described in chapter 2.
4.3.1 Calcium Imaging
Initially the cells were incubated with 6mM PhBto replicate the concentrations used
in clinical practice (193). Howeverafter treatment, the 96 well plate was viewed
under the microscope andthe cells were found to have lifted from the bottom of each
well. This was thought to have been dueto the acidic nature of PhB. Theeffect of
increasing concentrations of PhB on blood andSaline pH wasinvestigated (See
figure 4.1). It was shownthat the pH ofsaline dropped significantly on addition of
 
 
100uM PhB.
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on blood and saline pH at 37°C
8-
_—_ . . 2 saline 37°CT- SA a plood 37°C
6- n=3
x 5- a2.
4-
3-
2 i | T T T T 1
-10 -7 -6 -5 -4 -3 -2
[Phenoxybenzamine] log M
Figure 4.1- Effect of increasing concentrations of PhB on blood
and Saline pH. Increasing concentrations of PhB was addedto 50
ml humanblood containing 5000 i.u heparin or 145mMsaline at
37°C and the pH measured. Mean pH and SEMareplotted.
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It has previously been shown byothers that 11M PhB caused complete inhibition of
the response ofRA rings to NA (221). Wetherefore adopted this concentration for
all further experiments and the problemswiththe cells lifting were resolved.
RASMCcultured from 11 different patients were used for this study. Three batches
ofRASMCfrom a further 3 patients were not used as they developed a fungal
infection. Patient characteristics are shownin table 4.1.
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 Meanage (years) 67
 
Sex ratio (Male:Female) 7:4
Risk Factors (n)
Current Smokers 0
Ex-smokers 7
Non-smokers 4
Hypertension 6
Diabetes mellitus 1
Peripheral Vascular disease 2
Previous CVA or TIA 0
 Preoperative Medication (n)
  B blockers 7Calcium channel blockers 5ACEinhibitors 3Nitrates 9Potassium channel openers 3 
Table 4.1 — Patient characteristics (n=11)
Onday 0, none of the RASMCtreated with PhB showeda significant increase in
peak height of calcium-sensitive fluo-4 fluorescence on addition of NA. However,
all the cells that were not treated with PhB showedan increase in calcium
fluorescence with addition of NA, ECs 2.49 uM (95% CI 0.90-6.96 uM)(figure
4.2a). There was nosignificant difference between those treated with PhB andthe
untreated cells in response to angiotensin II addition (Table 4.2).
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On day 1 the PhBtreated cells had a similar ECs to the untreated cells, EC59 3.30
uM vs.2.671.M but the maximalincrease in fluorescence wassignificantly less
(figure 4.2b). The response to angiotensin II remained similar in the untreated and
PhB treated cells on this and all subsequent days (Table 4.3).
On day2, and the subsequent 2 days the concentration response curves weresimilar
in the treated and untreated groups(figure 4.2c,4.2d,4.2e,4.2f). Table 4.2 shows the
ECs9 ofNA oneachofthe days.
Similar responses were seen whenthecells were cultured in 100nM angiotensin II
(table 4.4 and figure 4.3), 100nM ET-1 (table 4.5 and figure 4.4), 100 nM
vasopressin (table 5.6 and figure 5.5), and 10M NA(table 6.7 and figure 6.6).
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Day PhB Treated PhB Untreated Significance
0 NS
1883.284+33.21 1884.13+430.59
1 NS
1904.778+26.03 1879.87+30.23
Z NS
1862.28439.59 1873+30.52
2 NS
1937.22+38.23 1878.73+31.24
4 NS
1973.5+26.7 1898435.36    
Table 4.2 — Peak increase in calcium fluorescence in responseto
addition of 100nM angiotensin Il in 11.M PhB treated and untreated
RASMC’s. n=18 wells for each groupin total (6 wells from 3
batches). Values are expressed as mean +SEM. Comparisonis
madeusing a paired student’st test.
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RASMCsincubated with no vasoconstrictor
 
 
  
Day PhBtreated PhB Untreated
Noradrenaline Noradrenaline
ECs (uM) ECs (uM)
(95%CTI) (95% CD
0 No response 2.49 (0.90-6.96)
1 3.30 (0.938-11.12) 2.92 (1.26-6.78)
2 3.30 (1.51-7.20) 2.62 (0.73-9.73)
3 3.89 (2.76-5.47) 2.41 (0.70-8.37)
4 3.37 (1.14-9.94) 2.80 (1.01-7.13)    
Table 4.3 — Shows ECs) NA (uM) and 95% confidenceintervals in
1M PhBtreated and untreated RASMC on Days 0-4. ECs9 were
calculated using Graphpad Prism version 3.02. Concentration
responsecurves were constructed by adding 0.1.M, 1M, 2uM,
4uM, 10uM and 100uM NA to 6 wells on each of 3 batches of
RASMC
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Figure 4.2c — Day 2
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Figure 4.2e — Day 4
Figure 4.2 — Concentration response curves for NA in 1n.M PhB
treated and untreated human RASMC ondays 0-4. Concentration
response curves were produced using Graphpad Prism version
3.02. They were constructed by adding 0.1uM, 1M, 2uM, 4uM,
10M or 100uM NAto 6 wells from each of 3 batches of RASMC.
Meanincreasein fluorescence + SEMare plotted. Figure 4.2a
represents 2 hours following PhB treatment, 4.2b 1 days after,
4.2c 2 days after, 4.2d 3 daysafter, 4.2e 4 daysafter
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RASMCincubated with 100nM AngiotensinIl
 
 
  
Day PhBtreated PhB Untreated
Noradrenaline Noradrenaline
ECs (uM) ECs (uM)
(95% CI) (95%CI)
0 No response 2.83 (1.43-5.63)
1 3.06 (1.92-4.85) 3.05 (1.73-5.38))
Z 3.44 (2.18-5.41) 2.26 (1.03-4.80)
3 3.50 (1.63-7.59) 3.27 (2.39-4.48)
4 3.16 (1.64-6.12) 2.56 (1.74-3.78)   
Table 4.4 — Shows ECs» NA (uM) and 95% confidenceintervals in
1uM PhBtreated and untreated RASMCincubatedin the presence
of 100nM angiotensin II on Days 0-4. ECs) were calculated using
Graphpad Prism version 3.02. Concentration response curves
were constructed by adding 0.1pM, 1M, 2uM, 4uM, 10uM and
100M NA to 6 wells on each of 3 batches of RASMC
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Figure 4.3 — Concentration response curvesfor NA in 1n.M PhB
treated and untreated human RASMCincubated in 100nM
angiotensin II on days 0-4. Concentration response curves were
produced using Graphpad Prism version 3.02. They were
constructed by adding 0.1uM, 1M, 2uM, 4uM, 10uM or 100nuM NA
to 6 wells from each of 3 batches of RASMC. Meanincreasein
fluorescence + SEM are plotted. Dueto scatter of points in the
PhB treated group on day 0 no curve could be constructed. Figure
4.3a represents 2 hours following PhB treatment, 4.3b 1 days
after, 4.3c 2 days after, 4.3d 3 days after, 4.3e 4 days after
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RASMCincubated with 100nM Endothelin|
 
 
  
Day PhB treated PhB Untreated
Noradrenaline Noradrenaline
ECs (uM) ECs (uM)
(95%CD (95% CI)
0 Not response 2.42 (0.93-6.23)
1 0.40 (0.0003-7.06) 2.64 (1.01-6.89)
2 2.95 (1.15-7.60) 3.23 (1.68-6.23)
3 2.47 (1.41-4.34) 3.30 (2.30-4.76)
4 3.51 (1.75-7.16) 3.92 (2.22-6.95)   
Table 4.5 — Shows ECs» NA (uM) in 1uM PhBtreated and untreated
RASMCincubated in 100nM endothelin | on Days 0-4. ECs») were
calculated using Graphpad Prism version 3.02. Concentration
responsecurves were constructed by adding 0.1y.M, 1M, 2uM,
4uM, 10uM and 100uM NAto 6 wells on eachof 3 batches of
RASMC
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Figure 4.4 — Concentration response curves for NA in 1M PhB
treated and untreated human RASMCincubated in 100nM
endothelin | on days 0-4. Concentration response curves were
produced using Graphpad Prism version 3.02. They were
constructed by adding 0.1yM, 1M, 2uM, 4uM, 10uM or 100uM NA
to 6 wells from each of 3 batches of RASMC. Meanincreasein
fluorescence + SEMare plotted. Figure 4.2a represents 2 hours
following PhB treatment, 4.2b 1 days after, 4.2c 2 days after, 4.2d 3
days after, 4.2e 4 days after
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RASMCincubated with 100nM Vasopressin
 
 
  
Day PhBtreated PhB Untreated
Noradrenaline Noradrenaline
ECs (uM) ECs» (uM)
(95%CI) (95%CI)
0 No response 2.36 (0.94-6.23)
1 1.58 (0.003-7.60) 2.68 (1.01-6.89)
2 2.96 (1.15-7.60) 3.24 (1.68-6.23)
a 2.47 (1.41-4.34) 3.33 (2.33-4.76)
4 3.54 (0.75-7.16) 3.92 (2.22-6.95)  
Table 4.6 — Shows ECs) NA (uM) (95%confidenceIntervals) in 11M
PhB treated and untreated RASMC incubated in 100nM
vasopressin on Days 0-4. ECs» were calculated using Graphpad
Prism version 3.02. Concentration response curves were
constructed by adding 0.1pM, 11M, 2uM, 4uM, 10uM and 100uM NA
to 6 wells on each of 3 batches of RASMC
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Figure 4.5 — Concentration response curvesfor NA in 1n.M PhB
treated and untreated human RASMCincubated in 100nM
vasopressin on days 0-4. Concentration response curves were
produced using Graphpad Prism version 3.02. They were
constructed by adding 0.1u.M, 11M, 2uM, 4uM, 10uM or 100uM NA
to 6 wells from each of 3 batches of RASMC. Meanincreasein
fluorescence + SEMareplotted. Figure 4.5a represents 2 hours
following PhB treatment, 4.5b 1 daysafter, 4.5c 2 days after, 4.5d 3
days after, 4.5e 4 days after
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RASMCincubated with 10uM Noradrenaline
 
 
  
Day PhBtreated PhB Untreated
Noradrenaline Noradrenaline
ECs (uM) ECso (uM)
(95% CI) (95% CI)
0 No response 2.36 (0.78-7.80)
1 1.58 (0.06-36.6) 3.52 (1.52-8.18)
2 3.03 (0.79-11.59) 2.24 (0.75-6.66)
2 3.24 (1.54-6.85) 2.74 (1.26-5.94)
+4 2.13 (1.00-4.98) 2.96 (1.85-4.73)  
Table 4.7 — Shows ECs) NA(uM) (95%confidenceintervals) in 1M
PhB treated and untreated RASMCincubated in 10uM NA on Days
0-4. EC;, were calculated using Graphpad Prism version 3.02.
Concentration response curves were constructed by adding
0.1uM, 1M, 2uM, 4uM, 10uM and 100uM NAto 6 wells on eachof 3
batches of RASMC
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Figure 4.6 — Concentration response curvesfor NA in 1u.M PhB
treated and untreated human RASMCincubated in 10uM NA on
days 0-4. Concentration response curves were produced using
Graphpad Prism version 3.02. They were constructed by adding
0.1uM, 1uM, 2uM, 4uM, 10uM or 100uM NAto 6 wells from each of
3 batches of RASMC. Meanincreasein fluorescence + SEM are
plotted. Figure 4.6a represents 2 hours following PhB treatment,
4.6b 1 daysafter, 4.6c 2 days after, 4.6d 3 days after, 4.6e 4 days
after
At no pointin time, in any group of experiments, wasthere a significant change in
the ECs for NA or a maximal increase in fluorescence in the PhBtreated cells
compared to the untreated group. This demonstrates that an overshootin a-
adrenoceptors does not occur in the human RA.
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4.3.2 Organ Culture Study
For these experiments, RA rings from 11 patients were used. Thepatient
characteristics are shown in table 4.8.
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Total numberofPatients 11
Meanage (years) 57
Sex ratio (Male:Female) 6:5
Risk Factors (n)
Current Smokers 0
Ex-smokers 4
Non-smokers 7
Hypertension 8
Diabetes mellitus 2
Peripheral Vascular disease 3
Previous CVA or TIA 0
Preoperative Medication (n)
B blockers 9
Calcium channel blockers 7
ACEinhibitors 5
Nitrates 9
Potassium channel openers 4 
Table 4.8 — Patient characteristics (n=11)
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There wasa decrease in the initial response ofthe rings to 90mM KC] on day1
compared with day 0, 3.86g +0.5 vs. 6.03g £0.56 (p=0.008). On day 2, only 2 out of
12 rings responded to 90mM KCl. Onthe 3rd day none, of the remaining 6 rings
from the 2 patients whose rings responded onday 2, responded to addition of
90mM KCI(see figure 4.7).
Responses to 90mM KCI
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Figure 4.7 -90mM KCI responses in 6mM PhBtreated RA rings on
consecutive days. Rings were incubated in DMEMat 37°C under
6g tension. Bars represent mean +SEM. * Denotessignificant
decreasein tension from the previous day (p=0.008)
At no time were weableto elicit a NA induced contraction in anyofthe rings, on
any day.
Vasopressin responses followeda similar pattern to the KCI responses. All ringsthat
responded to 90mM KCI, respondedto vasopressin. Noneofthe rings that did not
respond to 90mM KCIrespondedto vasopressin. Although there wasa significant
differencein the increase in tension seen in response to vasopressin on day 0
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compared to day 1 7.51g +0.61vs 3.82g 0.24 (p=0.0005) (Figure 4.8), when
expressed as a % of the KCI response, there wasnosignificant difference
125.8%+5.7 vs. 118.49+9.54 (p=0.53) (Figure 4.9).
Responseto 100nM
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Figure 4.8 - Responses to 100nM vasopressin in human RArings
on consecutive days. Rings were treated with 6mM PhBin
theatre. Bars represent mean +SEM. * Denotessignificant
decreasein tension from the previous day (p=0.0005)
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Figure 4.9 — Responses of human RArings cultured under on
consecutive days expressed as % ofinitial 90mMKCI responseof
that RA ring. Rings were incubated in DMEMat 37°C under 6g
tension. Bars represent mean +SEM. There wasnosignificant
difference in % 90mM KCI between days
Similar experiments were repeated with 3 rings from each of 4 patients with the rings
incubated underdifferent amounts of tension (2 patients (6 rings) 3g, 2 patients (6
rings) 12g) to investigate whether this affected the rings ability to contract beyond
day 2. Similar results were seen to those incubated under 6g of tension, with no
rings responding on day 3. Dueto the small numbersstatistical analysis was not
possible on this group of experiments.
126
4.4 Discussion
In human RASMCtreated with PhB,the response to NAisfully restored after
48hours. No "receptor escape” owing to up-regulation ofnewly formed
adrenoceptors was demonstrated. The results were similar in RASMCincubated in
the presence of 100nM angiotensin II, 100nM ET-1, 100nM vasopressin and 101M
NA.
Previously it at been shownthat there was an increased expression of
a adrenoceptors in rat aortic smooth muscle cells that were treated with PhB, when
incubated in the presence of angiotensin II (168) Using [Ca”*]. as a determinant of
receptor activation I was unable to demonstrate any increased response ofhuman
RASMCto NA whenincubated in angiotensin II. This may be a species specific
phenomenonalthough Mussa did not show anyincreasedsensitivity to
phenylepherine in his in vivo model, however, the levels of angiotensin II would not
have beenashigh in his in vivo modelas in the cell culture model (147)
In the organ culture model, we were not able to demonstrate any response to NA up
to 3 days following treatment with PhB. This was probably dueto failure of the RA
rings to maintain a contractile response past this time point.
Reviewingthe literature no other group appears to have beenable to see a
regeneration of a-adrenoceptorsin vitro. Harrison et al. maintained human RA rings
in an organ bath for 18 hours. At 18 hoursrings treated with PhB did not respondto
NA,howeverthe contractile force to KCl wassimilar to the start of the experiment
(222). Mussaetal. maintained rat aorta rings in an organ bath for 12 hours. At 12
hours rings treated with PhB did not respond to NA, (147) Velez et al. concluded that
PhB waseffective for at least 48 hours in dog radial arteries (221). Their
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experiments differed from the ones described here as they did not incubate the radial
arteries under tension. In the control group in this paper they showed responsesto
norepinephrine and phenylephrine remain similar when expressed as a % of the
initial KCI contraction after 24 and 48 hours (221). This is similar to what was
demonstrated in the experiments in this chapter with vasopressin. They do notreport
the actual strength of contraction, therefore one is unable to comment whether they
saw the same decrease in maximal force of contraction that was demonstrated above.
The decrease in force of contraction that was demonstratedis likely to be due to a
decrease in the contractile function ofthe artery rather than a decrease in membrane
receptors, becausethe contractile response to vasopressin wassimilar at 0, 24 and 48
hours when expressed as a percentage of the KCI response, although the actual force
pulled wassignificantly less.
These studies and the organ culture study carried out in this experimentare limited as
in vitro studies cannotaccuratelyreflect the clinical situation. To try and mimic
moreaccurately theclinical situation the rings were incubated in DMEMinthis
experiment which would hopefully provide the nutrients necessary for regeneration
of receptors. The rings were also incubated under tension in order to maintain a
contractile response. Despite these two measures we were unable to achieve a
response past 2 days. It maybethat continual contraction followed by relaxation (as
happensin vivo) is needed to maintain the contractile response.
Mussaet al.used an animal modelto look at the duration of action of PhB. They
found that 50% of the response to phenylephrine had returned at 24 hours (147).
This is similar to what we found in our RASMC model.
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In human RASMCthereis not an up-regulation ofthe e-adrenoceptors following
treatment with PhB and incubation in angiotensin II. This is important clinically
because plasmalevels of angiotensin II are raised following CABG. Treatment with
PhB hasnoaffect on the sensitivity of the human RA to NA..
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Chapter 5
Alternative Irreversible Vasodilators
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5.1. Introduction
In CABGsuperiorpatient survival rates and increased freedom from major adverse
cardiac events have been obtained in patients receiving LIMA grafts as opposed to
saphenousvein grafts (223). These results have encouraged surgeons towardsa
complete arterial revascularisation strategy. Promising patency rates obtained with
the RA have nowalso established this graft as a good alternative to the right IMA
(85). The RA is a comparatively reactive graft and vasodilator strategies are topically
applied by manysurgeonsin theatre and intravenously in the postoperative period to
ameliorate vasospasm, whichis believed to account for a proportion of early graft
failures (85;86). Spasm can occur both during harvesting and after the graft is
anastomosedto the heart, the aetiology is likely to be multifactorial (164). Factors
probably involved in the mechanism of spasm includesurgical trauma,locally
released vasoconstrictors, neural factors, and circulating hormones.
Various different drugs have been used to prevent and treat spasm. Pharmacological
strategies to prevent spasm usually consist of an intraoperative strategy and a
postoperative strategy. Vasodilator therapies include combinationsofnitrates,
phosphodiesterase inhibitors or calcium channel antagonists, and the recently
introduced irreversible « adrenoceptor antagonist PhB (85;88;224). The beneficial
effects of this agent have been shownin a recent prospective study. Patients
receiving PhB-treated grafts had a lowerlevel of perioperative myocardial injury and
a reduced incidence of adverse cardiac events when comparedto a
verapamil/glyceryltrinitrate treated group (88). The strategy of using an irreversible
inhibitor is very attractive, since it means that pharmacologically effective
concentrations can be applied selectively to the graft and the effect maintained in the
perioperative period. The benefits of irreversible antagonists in CABG have been
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shownas PhBtreatment completely abolishes NA-induced contraction in RA for up
to 48 hours in vivo (221).
Vasoconstrictors other than catecholamines, released into the plasma in the
immediate postoperative period can still reduce flow through the RA graft (86). As
well as an irreversible « adrenoceptor antagonist, PhB is a weak CaM antagonist
(225). However, in previous work we found that PhB hadnoeffect on the contractile
response to ET 1, angiotensin II, vasopressin and the depolarisation induced by KCl
(92). These results suggest that PhB will only prevent spasm dueto stimulation of
the a—adrenoceptor. Since the individual contribution of various vasoconstrictorsto
the generationofthe onset of spasm is unknown, we concluded that PhB should not
be used as the sole agent in the prevention ofRA spasm.
The RA producesstronger vasoconstriction than IMA responseto virtually all
vasoconstrictors studied (94;169;170;226); however vasoconstriction is equivalent
when normalised to account for the different vessel diameters in most cases.
However, normalised responses to both angiotensin II and vasopressin in the RA are
stronger and moresensitive than in the IMA,and furthermore occurirrespective of
the presence of endothelium (94;169;170). In addition, vasopressin-induced
contraction in the RA is comparatively resistant to milrinone and glyceryltrinitrate,
two of the most commonly used vasodilator strategies (94). The attenuation of the
vasopressin-induced contraction in RA grafts would beparticularly advantageous for
surgeons, since they may wishto use vasopressin to treat hypotensionin the
postoperative period (104;171).
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The aim hereis to test whether other irreversible antagonists, with a broader range of
activity and the potential to inhibit both receptor and non-receptor-mediated
contraction in the RA havethepotential for clinical application. We tested two drugs
used currently in otherclinical settings, fluphenazine mustard and minoxidil
sulphate. Fluphenazine mustardis a cell permeable,irreversible antagonist of CaM
(172), the cellular protein that translates an increase in intracellular calcium into
contraction.It is used clinically as an antipsychotic drug for the treatment of
schizophrenia and other psyschoses. Minoxidil sulphate binds irreversibly to the
vascular ATP-sensitive K* channel (Karp channel) andis used as an antihypertensive
agent (174). It is used clinically to treat severe hypertensionresistant to other drugs
and hair loss. Since to be ableto attenuate vasopressin induced contraction would
have clinical relevance, I examinedthe ability of fluphenazine mustard and minoxidil
to inhibit vasopressin induced contraction. Finally, the rho-kinase pathwaywill be
investigated as another possible common pathwaythat could be blocked to prevent
spasm if an irreversible agonist becomesavailable.
5.2. Methods and Materials
Samples ofRA were obtained from patients undergoing CABG.They wereharvested
as described in chapter 2. RA rings were set up and pre-tensioned in the organ bath
as described in chapter 2. 108 rings were used in total.
To test for functional contractility, arterial rings were first stimulated with 90 mM
KClandall other responses, including later KCl responses, expressed as % ofthis
response. Endothelial function, as evidenced bya vasodilatory response to 10 mM
acetylcholine in rings pre-contracted with 30 mM KCI, wasfoundto benegligible.
Responses were terminated by washing with three complete changes of media. Rings
pretreated with 100M fluphenazine-N-2- chloroethane, diHCl (SKF7171A, HCl;
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Merck Chemicals Ltd., Nottingham, UK) were incubated in the presence of the drug
for 40 minutes. Rings treated with minoxidil sulphate (Merck Chemicals Ltd.) were
incubated for 30 min at 10 mM,a concentration reported to completely reverse NA-
induced contraction in vascular smooth muscle (227). Following incubation with
fluphenazine or minoxidil sulphate the drug was removedby three complete changes
of media. Responsesto angiotensin II (Sigma, Poole, UK) were recorded within 20
min of drug washout and responses to Arg-vasopressin (Sigma)at either 30 or 120
min.
Responsesin treated rings.were normalised to control rings stimulated in parallel and
pretreated with vehicle alone (dimethylsulphoxide; DMSO). Y27632 (Merck
Chemicals Ltd.) or glyceryl trinitrate (DBL, Warwick, UK) which were added to the
organ chamber5 minprior to and during agonistaddition.
5.2.1 Data analysis
Data is presented as mean + standard deviation of the mean (SD), where n refers to
the numberofindependent samples tested. The threshold vasopressin concentration
was defined as the concentration at which tension wassignificantly raised above
baseline tension. Data were tested for normaldistribution and appropriate
comparisons were undertaken asthe analysis dictated using a one-way ANOVAand
a Bonferroni correction for multiple comparisons. All analyses were carried out
using the program Arcus QuickStat Biomedicalusing a p value of 0.05 (Hearne
Scientific Software, Dublin, Eire).
134
5.3 Results
RA samples were collected from 31 patients. 108 rings were usedin total. The
clinical characteristics of these patients are given in table 1.
 Total numberofPatients 31
Meanage(years) 63
Sex ratio (Male:Female) 2338
Risk Factors (n)
Smoking 6
Hypertension 15
Diabetes mellitus 6
 Preoperative Medication (n)  B—blockers 22Calcium channel blockers 14ACEinhibitors 11Nitrates 15Potassium channel openers 9
Table 5.1 - Patient Characteristics
Theinternal diameter at a pressure of 100 mmHgwas3.8 + 0.9 mm.Totest for
functional vasoconstriction, sections ofhuman RA werestimulated with 90 mM KCl
that raised tension from a meanbasal value of 1.93 +0.92 g (n= 31) to 7.70 + 3.66 g.
Data wascollected from distal arterial sections treated with PhB in theatre (6.26 +
2.18 g; n= 17) and proximalsections treated with papaverine (9.72 + 4.49 g; n= 14).
Aspreviously reported by other investigators (228), proximal sections gave
significantly higher KCl-induced contraction than distal (p < 0.05). All data were
therefore expressed as % ofthis initial KCl] response.
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5.3.1 Vasoconstrictor Responsesin the Radial Artery
Robust concentration dependent contraction was observed to vasopressin and
angiotensin II giving average maximal responses of 109+16% KCI (n=13;95%
confidenceinterval 104-115) and 95.4£6% KCl (n=14; 95% confidenceinterval 79-
104) respectively. ECs values (95% confidenceintervals) of 0.51nM (0.27-0.98)
and 3.54nM (1.73-7.24) were obtained for vasopressin and angiotensin II
respectively. Proximal samples gave significantly higher maximal responses to
angiotensinII and vasopressin (p<0.05), but when normalized to KC] there was no
significant difference between proximal and distal samples (p=0.44). Representative
traces are shownin Figure 5.la&b.
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Figure 5.1 - Representative traces from individual rings of RA
showing standard responsesto increasing concentrations of
either vasopressin or angiotensinIl. Responses are shownin
relation to aninitial response to 90 mM KCI(A). Following
washout(B) of the KCI response with two complete changesof
media, rings were stimulated with increasing concentrations of
either vasopressin (a) where C = 0.1, D= 0.3, E= 1, F= 10, G=30
and H = 100 nM vasopressin)or angiotensin Il (b) where C = 1, D=
3, E=10, F= 30 and G = 100 nM angiotensinIl).
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Whilst maximal responses to both KCIand angiotensin II returned to baseline
following agonist washout within 10 min, vasopressin-induced contraction was
significantly reversed only by glyceryl trinitrate concentrations greater than 211M.
An ECsvalue for the reversal of maximal vasopressin-induced contraction with
glyceryltrinitrate was 89.12uM (n=6).
5.3.2 Effects of treatments against vasopressin induced
contraction
Pre-treatment with fluphenazine consistently reduced the maximal vasopressin-
induced contraction (Figure 5.2a) and significantly increased the ECs (Table 5.2)
whereasarterial rings pretreated with minoxidil failed to show anysignificant
effects. Since vasopressin-induced contraction wasnot reversed by agonist washout,
the effects of the Rho kinase inhibitor Y27632 werealso tested against vasopressin-
induced contraction and compared with glyceryltrinitrate (Figure 5.2b). Treatment
ofarterial rings with 104M Y27632 reduced the basal tension by 33+7% (n=5) and
significantly reduced the maximal vasopressin-induced contraction (Figure 5.2) and
significantly decreasedtheaffinity of the response (Table 5.2). Fluphenazine mustard
and Y27632 increased the threshold concentration which significantly raised tension
above basal values from 0.3nM in controls to 1.0nM in treated samples from both
groups.
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Figure 5.2 - Effect of treatments against vasopressin-mediated
vasoconstriction. Cumulative concentration response curves were
obtained to vasopressin following pretreatment (a) with vehicle
alone (control; n = 12), 100 pM fluphenazine mustard (n = 6) or 10
uM minoxidil sulphate (n = 6) or in the presence of (b) 10 pM
Y27632 (n = 5) and 22 uM (n= 5) and 220 pM (n= 5) glyceryl
trinitrate, where n refers to the numberof independent samples
tested. Average responses + SD,are shownrelative to a
contractile response to 90 mM KCI applied prior to treatment. See
table 5.2 for statistical comparisons
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Vasopressin
|
Control Minoxidil Fluphenazine Y27632 Glyeryl Glyeryl
mustard trinitrate trinitrate
(22uM) |(220uM)
N 13 7 7 5 5 5
Max
Response 109416 119416 *72+12 *94+13 99+12 81+11
(%KCl)
Confidence 104-115 134-105 81-63 110-73 114-83 95-68
Intervals
(95%)
ECs (nM) 0.51 0.74 *1.26 *1.54 1.65 a
Confidence 0.27-0.98
|
0.37-1.45 0.60-2.63 0.60-3.89 0.49-5.62 0.93-8.13
Intervals
(95%) (nM)  
Table 5.2 - Data is expressed as % response to 90mM KCI.
*Denotes significant differences ( p < 0.05) between treatment
groups and controls by ANOVAusing the Bonferroni correction
for multiple comparisons
5.3.3 Effect of minoxidil sulphate and fluphenazine mustard
pretreatment against angiotensinIl and KCl-induced
vasoconstriction
 
Maximal responsesto angiotensin II were significantly reduced bypre-treatment
with fluphenazine mustard but not minoxidil when compared to controls (Table 5.3).
No measurable change in ECs values for angiotensin was observed with either
treatment. In addition fluphenazine mustard significantly reduced contraction
elicited by 90mM KCI by 48+15% when comparedto control response. In control
rings, KCI responses were maintained, giving average values 107 + 21% ofthe initial
contraction (n = 8). Pretreatment with minoxidil sulphate showed no measurable
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effect against KCl-inducedcontraction giving an average response 112+ 17% (n=6)
of the initial contraction
 
     
Angiotensin II Control Minoxidil Fluphenazine
N 14 7 6
Max Response
(%KCl) 95.4+6.4 80428 *54+20
Confidence 79-104 107-55 75-32
Intervals (95%)
ECs0
(nM) 3.54 5.24 7.41
Confidence 1.73-7.24 2.04-13.80 0.3-173nM
Intervals (95%)
(nM)
Table 5.3 - Comparison of maximal responsesandaffinity of
responseto angiotensinIl in human RApretreated with minoxidil
sulphate or fluphenazine mustard. Data is expressed as %
response to 90 mM KCI. *Denotes significant differences (p<
0.05) between treatment groups and controls by ANOVAusing the
Bonferroni correction for multiple comparisons
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5.4 Discussion
The major finding of this work wasthat pre-treatment ofRA grafts with the
irreversible CaM inhibitor, fluphenazine mustard (SKF7171A), significantly
attenuated receptor-mediated contraction evoked by angiotensin II and vasopressin,
and depolarisation-induced contraction by high potassium. CaM is the cellular
protein, which integrates the calcium response and activates the myosin light chain
kinase responsible for contraction. Since an increase in smooth muscle calcium is the
primary initiating stimulus for contraction, this makes CaM an excellent target for
inhibiting contraction evoked by a wide range of agonists. This study also
demonstrated that the reversible rho kinase antagonist, Y27632 reduced the maximal
vasopressin-induced contraction.
Wechoseto test the actions of the inhibitors against vasopressin and angiotensinII
because normalised responsesto both angiotensin II and vasopressin in the RA are
stronger and moresensitive than in the IMA,and occurirrespective of the presence
of endothelium (94;169;170) therefore it is important to be able to attenuate these
responses. In addition, vasopressin-induced contraction in the RA is comparatively
resistant to milrinone and glyceryltrinitrate, two of the most commonly used
vasodilator strategies (94). The inhibition of the vasopressin-induced contraction in
RA grafts would be particularly advantageous for surgeons, since they may wish to
use vasopressin to treat hypotension in the postoperative period (104;171).
Vasopressin has been shownto be a potent vasoconstrictor in the IMA (101) with
calcium channel antagonists causing only limited relaxation and GTN causing nearly
full relaxation butfailing to prevent contraction evoked by vasopressin. Contractions
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could be fully blocked by the V1 receptor antagonist 1-deaminopenicillamine, 4-
valine, 8-D-AVP (101).
Wehave previously shownthat the only currently used irreversible antagonist, PhB,
has no effect on preventing angiotensin II and vasopressin induced contraction of the
RA.As spasm islikely to be multi-factorial, blockage of these vasoconstrictors may
be clinically important.
5.4.1 Calmodulin inhibitors
Fluphenazine mustard (SKF7171A) significantly attenuated receptor-mediated
contraction evoked by angiotensin II and vasopressin, and depolarisation-induced
contraction by high potassium concentrations.
Although effects were only measured up to 2 h after treatment they would be
expected to be similar in duration to PhB, since irreversible interactions of this type
will last until the smooth muscle cells of the vessel wall replace the inactivated
protein . Inhibition with fluphenazine mustard should therefore last well into the
postoperative period (147); howeverit would be useful to verify this in vivo. The
animal model used to confirm the duration of action of PhB would suit this purpose
(147). Using this model it was demonstrated that the effects of PhB lasted for 16 h in
vivo.
Aswell as being involved in contraction of vascular smooth muscle, CaM is
involved in a numberofcellular functions that cause vasodilatation. Nitric oxide is
synthesised by vascular endotheliun by a family of CaM-dependent NO
synthases.(NOS). Caveolin, the principle structural protein in calveolae, interacts
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with endothelial NOS (eNOS)to inhibit it in a reversible process modulated by CaM.
CaMalso increases Ca" release from sarcoplasmicreticulum and reduces Ca”*
uptake. Fluphenazine mayalso therefore cause vasodilatation by inhibiting these
processes.
5.4.2 Potassium Channel Openers
Wefound 10mM minoxidil sulphate to be ineffective at inhibiting contractions in the
RA.This occurred irrespective of the use of potassium channelblockers in the
preoperative medication. Interestingly, minoxidil sulphate demonstrates a high
degree of tissue andspeciesselectivity. For example, minoxidil sulphate is a potent
vasodilator in rat aorta but not in rabbit aorta or rat mesenteric artery, whereas other
Karp channel openers were equally effective in all tissues (227). The lack of effect
measured in human RA in this study indicates that minoxidil sulphate has poor
activity in this vessel also. It is unlikely that the lack of effect is due to the
concentration used, as we choseto use a concentration more than ten times that
reported as maximal.
5.4.3, Rho Kinase Inhibitors
The effect of the reversible Rho kinase inhibitor Y27632 wasalso investigated. The
sustained phase of vascular smooth muscle contractionis thought to involve Ca”*
sensitization (179). It is believed to be this phase that initiates clinical vasospasm in
cerebral arteries (180). The major mechanism ofthe Ca”* sensitization of contraction
is through the inhibition of the smooth muscle myosin light chain phosphatase,
resulting in increased myosin light chain phosphorylation and smooth muscle
contraction at a constantintracellular calcium level (179). It has been recognised
that the monomeric G protein Rho and its downstream target Rho-kinase can
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participate in sustained vasoconstriction by phosphorylating and inhibiting myosin
binding (181). Rho-kinase has been proposedto play a variety of vascular smooth
muscle disorders including hypertension, coronary and cerebral vasospasm
(180;182;183).
Rhokinaseis activated by 5-HT, ET 1 and thromboxane A2 [17], NA (229) and by
the stress hormonecortisol (230). This study demonstrated that Y27632 reduced the
maximal vasopressin-induced contraction Therefore the involvement of the Rho
kinase pathway in vasopressin induced contraction in the RA indicates that both
sensitivity of the graft to vasopressin. This may be pertinent to the management of
postoperative contraction in RA grafts or the use of vasopressin in the management
of hypotension following CABG (171), particularly as vasopressin-induced
contraction in RA is refractory to two of the most commonlyused vasodilator
strategies (94).
The mRNAexpression of rho-kinase is enhancedin inflammatory and
atherosclerotic lesions causing hypercontraction of the artery. In cultured human
coronary artery smooth musclecells the expression of rho kinase is enhanced by
angiotensin II and interleukin 18. This could be an important contribution to
vasospasm following CABGasboth levels of angiotensin II and interleukin 1 are
raised (91). .
As well asits role in vascular smooth muscle contraction rho-kinaseplays a role in
mediating various othercellular functions. These include actin cytoskeleton
organisation (231), cell adhesion and motility (232), cytokenesis (233) and gene
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expression (234). All of these may be involvedin the pathogenesis of
atherosclerosis. Furthermore, rho-kinase is involved in endothelial contraction that
increases endothelial permeability and hence enhancesatherosclerosis (235). In
porcine femoralarteries balloon injury-induced neointimal formation was
significantly reduced by Y27632 (236). As well as preventing spasm,the long-term
use of rho-kinase inhibitors may also suppress the developmentof atherosclerosis.
The rho-kinase inhibitors fasudil and Y 27632 act in a competitive manner with ATP
(237). They decrease the myosin light chain phosphatase inhibition and subsequent
elevation ofmyosin light chain phosphorylation, mediated by receptor stimulation or
the activation of G-proteins. They have no effect on the transient or sustained
increasein intracellular calcium (238;239). Y2632 was as effective as high dose
GTNat preventing vasopressin induced contraction of the RA in our study. These
large concentrations of GTN could not be achieved systemically as they would cause
profound hypotension. Fasudil has been shownto be able to prevent vasospasm at
clinically useful concentrations (240). Also there is the problem with tolerance to
long-term GTN. This has not been shownto be a problem with rho-kinaseinhibitors.
The dropin basal tension seen in the RA on addition ofY27632 has been described
in the mammary artery by Batchelor ef al. (158). Rho A appearsto be basally active
(241), therefore it follows that Y27632 will inhibit resting tone. This does not seem
to be the casein the coronary arteries in vivo, as treatment with fasudil had no effect
on nonspastic segmentsof artery following acetylcholine induced vasospasm (240).
Also it has been shownthat rho-kinase is involved in the increased systemic vascular
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resistance in hypertensive patients but not normotensive controls (240). It remains to
be seen whether the inhibition of the basal tone of the RA and IMAoccurs ex-vitro.
Wechoseto pretreat the RA with rho-kinase inhibitors rather than apply a
vasoconstrictor and reverse any spasm because wefeel prevention of spasm is the
goal. It has previously been suggested that pretreatment with Y27632 is less
effective than application following the vasoconstrictor agonist (241;242). This
discrepancy does not appear to be a major factor in human conduit artery (158). It
also does not appearto be a factor in vivo in human coronary arteries (240).
Y27632 wasas effective at preventing contraction of the RA as high concentrations
of GIN. Thisis not suprising as nitric oxide induces vasodilatation of vascular
smooth muscle by a cGMP dependent kinase (243). Since NO dilatations occur
without changesin intracellular calcium concentration, calcium sensitisation must be
involved. Myosin light chain phosphatase is activated by NO,stimulation of the rho
A/tho kinase pathway antagonises the effects ofNO that, in turn, can be restored by
Y27632 suggesting a role of the rho kinase pathway in NO. The RA undergoes a
period of hypoxiaprior to grafting. Hypoxia has been shownto cause
vasoconstriction in the pulmonary artery or saphenousvein (244). This mayin part
be due to a decreased expression of endothelial nitric oxide synthetase (eNOS). This
reduction in eNOSexpression can be prevented by rho-kinase inhibitors (244). Thus
rho-kinase inhibitors may be beneficial in RA storage solutionspriorto grafting, not
only to cause vasodilataion directly through increasing myosin light chain
phosphataseactivity, but also but by preventing any decrease in eNOSexpression
induced by hypoxia.
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In conclusion the rho-kinase inhibitor Y27632 wasas effective as high dose GTN at
preventing vasopressin induced contraction of the human RA in vitro. Although
Y27632is notclinically available, fasudil, another rho-kinase inhibitor is available in
intravenousand oral preparations. As well as using long term administration of rho-
kinase inhibitors, the developmentof an irreversible rho-kinase inhibitor would allow
a once off treatmentin theatre prior to grafting to prevent spasm.
5.4.5 Conclusions
Fluphenazine mustard has potential to be developed as a useful treatment in the
prevention of RA spasm and demonstrates long-lasting effects against
vasoconstriction induced by several unrelated agonists. Further studies are required
to investigate the duration and breadth of effect of fluphenazine mustard against a
broader range of vasoconstrictors in RA. The developmentof clinically useful rho-
kinase inhibitors may also provide a future therapeutic opportunity for the
managementofarterial contraction in the postoperative period, especially if rho-
kinase inhibitors can be developedto give long-lasting protection (246).
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Chapter 6
Conclusions
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6.1 Summary of key findings
Theresults of the experimental work in this thesis have shownthatthere are a large
numberofnerve endingsin the wall of the human RA. Stimulation ofRA rings with
tyramine caused a contraction that is blocked bythe irreversible a-adrenoceptor
agonist, PhB. After relaxation with GTN,further addition of tyramine did not cause
a contraction suggesting depletion of the nerve endingsin the wall of the RA ofNA.
Stimulation of RASMCbytyraminedid not cause an increase in peak calcium
fluorescence, but direct stimulation with NA did. It was therefore concluded that
nerve endings in the wall of the RA contain significant amounts ofNA and may
therefore cause spasm as they degenerate. Treatment ofRA rings with reserpine
decreased the strength of contraction to tyramine. This may be a way of
degranulating nerve endingsclinically, thus reducing the problem of spasm.
In human RASMCthereis not an over-expression of a-adrenoceptors after treatment
with PhB, even whencultured in the presence of other vasoconstrictors including
angiotensinII.
Theirreversible CaM inhibitor fluphenazine mustard significantly lowered the
maximalcontractile response in human RA rings to vasopressin and angiotensinII,
and significantly lowered the ECs in human RA ringsto vasopressin. The
irreversible KCO, minoxidil sulphate had no effect on the maximal contractile
response and ECso in human RA rings to vasopressin and angiotensinII.
Fluphenazine mustard maytherefore be used to prevent spasm in the RA due to a
numberofdifferent vasoconstrictors.
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The rho-kinase inhibitor, Y27632 significantly lowered the maximal response and
the ECso in human RA rings to vasopressin. The rho-kinase system could be blocked
in the future, if an irreversible rho-kinase inhibitor becomesavailable to prevent
spasm in the RA.
6.2 General Conclusions
It is now widely accept that the IMA should be used as a conduit to the LAD. The
use of more than onearterial graft has not generally been accepted. Only 15% of
patients undergoing CABGin the UK have morethan onearterial graft (26). There
is strong evidencein theliterature to support the use ofBIMA in termsof survival
and fewer ischemic cardiac events (17-19). The main reason for the lack of use of
BIMAisprobably the increased incidence of sternal wound infections and the
greater complexity of the operation. Use of the RA doesnotincrease the complexity
of CABGandis associated with a lower incidence of conduit harvest woundsite
infection. The reasons for lack of widespread use of the RA are probably two fold;
firstly the lack of large randomised controltrial showing an increased patency rate of
the RA overthe long saphenousvein, and secondly the fear of spasm of the RA.
Although excellent short and mid-term patency rates of the RA have been
demonstrated, only Possati has published long-term results (44). This show superior
patencyrates to historical patency rates of the saphenous vein. The patencyrates of
the saphenous vein have improved overthe last 10 years due to changesin surgical
technique andtheroutineuseofstatins and asprin postoperatively, and thereforeit is
unfair to comparethe patency rates of the RA to that of the saphenousvein 10 years
ago. Thereislittle scientific evidence comparing the RA and the SV. Trials
comparing the two conduits are in progress andthe interim results of one ofthese
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trials has showed no difference in patency at 5 years or a difference in clinical events
(46). Long-term results are awaited, as this is when the patencyrates of the RA is
expected to be greater.
Thetrue incidence of spasm of the RA is unknown anddifficult to properly assess.
The incidence of spasm quotedin the literature is between 0 and 10%
(34;40;48;49;56-58). These figures are based on elective angiography during the
first year following surgery. The true incidence of spasm is therefore probably
higher than this as the RA is believed to be more prone to spasm in the early
postoperative period, when native coronary flowisstill present, and hence may go
undetected.
The use ofthe irreversible « adrenergic blocker, PhB provides an attractive new way
to treat spasm in the post-operative period (143). However, it makes one major
assumption, that spasm is due to a-adrenergic agonists. It is not known what
contribution circulating catecholamines make to spasm. Levels of circulating NA is
raised by 3-4 timesforthe first 24 hours following cardiac surgery (91). These
levels are 10 times less than that required to cause contraction ofRASMC or RA
rings in-vitro. NA is released from sympathetic nerve terminals, local concentrations
ofNA will therefore be higher than systemic concentrations, and maybeat sufficient
levels to cause spasm. We have shownthat sympathetic nerve endings in the wall of
the RA have the potential to degranulate and cause a contraction similar in strength
to the maximal response to NA. Degenerating nerve endingsin the wall ofthe artery
provides an attractive hypothesis for the mechanisms of spasm in the postoperative
period and could explain why spasm can occur many weeksfollowing surgery when
one would have expected the effects of surgical traumato the artery to have resolved
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and circulating levels of catecholamines and other vasoconstrictors to have returned
to normal.
If degenerating nerve endings are a cause of spasm, PhB would provideanattractive
wayofpreventing spasm in the initial postoperative period. We have shownthat the
effects of PhB last for up to 48 hours. We were unable to demonstrate an overshoot
in a adrenoceptors following PhB treatment ofhuman RASMC,suggesting there
will not be an increased propensity of spasm of the RA following PhB treatment.
After 48 hours the effects of PhB are no longer present and therefore one has to look
at other methods to prevent spasm. Calcium channel blockers andnitrates are the
most commonlyused drugsbutthereis little evidence to show they are of any benefit
(44;45). Nerve endings may be degranulated at the time of surgery to prevent them
releasing NA. Tyramine degranulates nerve endings, howeverthe nerve endingsare
probablystill capableofrefilling their vesicles by reuptaking NA or producingit.
Reserpine inhibits the amine uptake process in the vesicle membrane and thereby
allows leakage ofNA into the cytoplasm ofthe nerve cell where it is broken down by
neuronal MAO.Theeffects of reserpine should last at least 10 days because recovery
of neuronal function depends on synthesis of new vesicles and their transport to the
axon terminals, the effects may however be permanentif the nerves are no longer
functional. We have demonstrated that reserpine prevents an increase in tension of
RA ringsin responseto the addition of tyramine.
Although webelieve degenerating nerve endingsto be one of the majorcontributors
to spasm of the RA,the aetiologyis probably multi-factorial, and therefore any
treatment strategies should take this into account. Surgical techniques have
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improvedoverthe last few decades, which probablyled to the revival of the RA.
Various vasoconstrictors have been implicated in the cause of spasm and antagonists
to these vasoconstrictors could be used to treat spasm. This would mean using a
cocktail of drugs, many ofwhich are not yet available clinically and most of which
are reversible. A more feasible strategy is to block the contractile mechanism further
downstream whereinhibition of one enzyme will prevent vasoconstriction due to a
numberofstimuli. This is the principle for the use of calcium channel blockers and
phosphodiesterase inhibitors. Other drugsthatfit into this category are CaM
inhibitors, KCO or rho-kinase inhibitors. The experimental work in this thesis has
shownthat the irreversible CaM antagonist fluphenazine mustard is effective at
decreasing contractions ofhuman RA rings due to vasopressin and angiotensinII.
Minoxidil, an irreversible KCO wasineffective.It is therefore unlike that it has any
role in the prevention or treatment of spasm.
Fluphenazine maytherefore have role as an antispasmodic. Fluphenazine acts in a
completely different way to other commonlyused antispasmodics such as GTN and
phosphodiesteraseinhibitors, so its effects may be additive to any of these other
agents, if used in combination with them.
The rho-kinase pathwayis another pathway that may be blockedto havean effect on
a wide range of agonists. The rho-kinase inhibitor Y27632 waseffective in
increasing the ECso and decreasing the maximum contraction to vasopressin and
angiotensin II. Although Y27632is not available clinically, fasudil, another rho-
kinase inhibitor, is available in an oral and intravenous preparation and could be used
in the intra-operative and postoperative period. As yet rho-kinase inhibitors are not
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irreversible. An irreversible rho-kinase inhibitor would be a veryattractive drug in
the prevention of spasm of the RA.
The use of the RA hasincreased overthe past five years. The attractions of the RA
to the surgeon are immediate and obvious;it is a versatile conduit that can be
harvested easily and safely, it has handling characteristics superior to otherarterial
grafts, and it reaches comfortably any target vessel (247). It has been shownto have
excellent mid and long-term patencyrates (42;45;48;49;57;248-250). The
superiority over the long saphenousvein has yet to be shown, however midterm
results are similar and on the basis of long term patency rates ofRA grafts and with
the previous experience ofpersisting patencyinarterial grafts and occlusion of vein
grafts the continued use of the RA isjustified. With better understanding ofthe
mechanismsof spasm and new drugs becomingavailableto treat it, spasm will not
be the problem feared by some.
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PH ofphenoxybenzaminein storage solutions
Taggart initially described using 6mM PhB (193). This was the dose used in theatre
at The Cardiothoracic Centre, Liverpoolat the time the experimental workforthis
thesis wascarried out. In the experiments described in Chapter 4, problems with the
cells lifting from the bottom of the 96 well plates was encountered. Oneofthe
reasonsfor this was thoughtto be the acidic nature of PhB. This was therefore
investigated. Asclinical practice differs from these in-vitro experiments, because the
PhB is placed in blood, the effect on blood pH wasalso investigated. The
experiments were repeated at room temperature and 37°C.
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concentration
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Figure A1 — Effect of increasing phenoxybenzamine
concentrations on saline pH at room temperature (n=3). Mean
responses +SEMare shown.
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Figure A2 — Effect of increasing phenoxybenzamine
concentrations on saline pH at 37°C. (n=3). Mean responses
+SEM are shown.
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Figure A3 — Effect of increasing phenoxybenzamine
concentrations on heparinised blood (100iu/ml) pH at 37°C (n=3).
Mean responses +SEMare shown.
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It had been shown byothers that a concentration of 11M PhB completely blocks the
contractile response to NA (221). Dueto this and the findings described above the
surgeons at The Cardiothoracic Centre, Liverpool, now use a lower concentration of
PhB
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Potentiation of noradrenaline response by vasopressin in
RASMC
As mentionedin this thesis previously the cause of spasm is unknown. Thelevels of
vasoconstrictors in the plasma post-operatively are insufficiently raised to cause a
contraction of the RA in vitro alone, it has been shownthatthere is a synergistic
effect between some vasoconstrictors e.g. NA and vasopressin. It may therefore be a
combination of vasoconstrictors that are the cause of spasm in vivo.
Various concentrations ofNA was added to RASMCon 96 well plates containing
various concentrations of vasopressin. The peak increase in fluorescence was
measured(see figure A5).
Potentiation of Noradrenaline
Response by Vasopressin           4000- 2umol norad7 10umol norad5 3000-°Oc™ 2000-@7)oo Pavan© 1000-£ 0 it ‘No VP 0.01 0.inmol ‘4nmol
Vasopressin concentration
Figure A5 — Peakincreasein fluorescence of RASMC on addition
of 2 or 10uM NAin the presenceof varying concentrations of NA.
n=18 wells from 3 batches. Bars show meanof 5 readingsfor
each well. Error bars represent SEM.
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Detailed anatomyof the Radial artery
The forearm and handreceivesits blood supply from the radial and ulnararteries.
The RA appearsto be a direct continuation of the brachialartery, but it is smaller in
calibre than the ulnarartery. It commencesatthe bifurcation of the brachial artery,
just below the elbow crease. It passes along the radial side of the forearm to the
wrist where it winds backward, aroundthelateral side ofthe carpus, beneath the
tendons of the Abductor pollicis longus and Extensorpollicis longus and brevis.
Finally it passes forward between the two headsofthefirst interosseous muscles,
into the palm. In the palm it crosses the metacarpal bonesandat the ulnar side ofthe
handit joins with the deep palmarbranchofthe ulnarartery to form the deep palmar
arch.
Branchesofthe RA in the forearm include;(1) the radial recurrent artery which arises
immediately below the elbow, supplies muscles around the elbow-joint, and
anastomosing with the terminal part of the profunda brachi artery. (2) Muscular
branches which supply musclesonthe radial side of the forearm. (3) The palmar
carpalartery is a small vessel which runsacross the front of the carpus and
anastomoses with the palmarcarpal branch ofthe ulnarartery. This anastomosisis
joined by a branch from the palmar interosseous above, and by recurrent branches
from the deep palmararch below,thus forming a palmar carpal net-work which
suppliesthe articulationsof the wrist and carpus.(4) Superficial palmar branch
whicharises from the RA, just where the RA is about to wind aroundthe lateral side
of the wrist. It anastomoses with the terminal portion ofthe ulnar artery, completing
the superficial palmararch.
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At the wrist the RA gives off four branches the dorsal carpal artery and thefirst
dorsal metacarpal artery. The dorsal carpal branchis a small vessel which arises
beneath the Extensor tendons of the thumb; crossing the carpus transversely toward
the medial border of the hand, it anastomoses with the dorsal carpal branch of the
ulnar and with the palmar and dorsal interosseousarteries to form a dorsal carpal
network. From this network are given off three slender dorsal metacarpalarteries.
Neartheir origins they anastomose with the deep palmararch by the superior
perforating arteries, and neartheir points of bifurcation with the common palmar
digital vessels of the superficial palmararch bythe inferior perforating arteries. The
first dorsal metacarpal arises just before the RA passes between the two headsofthe
first Interosseous dorsalis and divides almost immediately into two branches which
supply the adjacentsidesofthe thumb and index finger; the radial side of the thumb
receives a branch directly from the RA
In the hand the RA givesrise to the arteria princeps pollicis. It arises from the RA
just as it turns medial towardsthe deep part of the hand; it descends between thefirst
interosseous dorsalis and adductorpollicis obliquus, along the ulnarsideofthe
metacarpal boneofthe thumbto the baseofthe first phalanx, where it lies beneath
the tendonofthe flexor pollicis longus and divides into two branches. These make
their appearance between the medialandlateral insertions of the adductorpollicis
obliquus, and run along the sidesof the thumb, forming on the palmarsurface of the
last phalanx an arch, from which branchesare distributed to the integument and
subcutaneoustissue of the thumb. Thearteria palmaris indicis radialis arises close to
the arteria princepspollicis, descends between the first interosseus dorsalis and
adductorpollicis transversus, and runsalong the radial side of the index fingerto its
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extremity, where it anastomoses with the proper digital artery, supplying the ulnar
side of the finger.
The deep palmararch is formed by the anastomosis of the terminal part of the RA
with the deep volar branch ofthe ulnar artery. It lies upon the extremities of the
metacarpal bonesand on the interossei muscle, being covered by the adductor
pollicis obliquus, the flexor tendonsofthe fingers, and the lumbricales.
The superficial palmar arch is formed by the ulnar artery, and is usually completed
by a branch from the volaris indicis radialis artery, but sometimes by the superficial
palmararteryor by a branch from thea. princepspollicis artery. The arch passes
acrossthe palm, describing a curve, with its convexity downward.
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RESEARCH INTO VASCULAR DISEASE AND BYPASS GRAFT
FAILUREAT THE CARDIOTHORACIC CENTRE
PATIENT INFORMATION
You are being invited to assist in research studies being performed at
the Cardiothoracic Centre, in collaboration with the University of
Liverpool. Before you decideit is important for you to understand why
the research is being done and whatit will involve. Please take time to
read the following information carefully and discussit with others if you
wish. Askusif there is anything that is not clear or if you would like
more information. Take time to decide whetheror not you wishto take
part.
Purposeof the studies
Coronary artery disease is more widespreadin the North West than nearly
any other region in the World. In this condition fatty blockages obstruct the
coronary arteries. Coronary bypass surgery has becomea routine operation
and over 4000 operations are performed annually in the North West region.
The operation involves re-routing blood around the obstruction using a blood
vessel(graft) taken from elsewhere in the body. Although the operationis
highly beneficial for most patients, chest pain (known as angina) frequently
recurs, affecting 50% of patients by 10 years. This pain recurs as a
consequenceofthe grafts themselves becoming blocked.In collaboration
with the Department of Human Anatomyand Cell Biology at the University of
Liverpool, we haveinitiated a programmeof research aimed at
understanding and preventing bypassgraft failure. To do this we are
analysing the behaviourof sections of arteries and veins and also extracting
and growingdifferent cell types from within blood vessels using a process
termed tissue culture. The programme of research involves severaldifferent
studies examining different aspects of bypassgraft failure and vascular
disease processes.
WhyhaveI been chosen?
After your bypass surgery there may be small piecesof arteries or veinsleft
over which were not required for your treatment and which would otherwise
be discarded. Weareinviting you to allow us to use these excesspiecesfor
our research.
What are the possible disadvantages andrisks of taking part?
There are no disadvantagesto giving your permission for us to use these
surplus piecesof tissue for research.It will not affect your surgery or your
subsequenttreatmentin any way.
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Whatare the possible benefits of taking part?
There are no personal benefits to you in taking part and your decision will not
affect your treatment in anyway. However, we hopethatthe information we
get from this research mayhelp to improve the outcomeof bypass surgery
for future patients.
Whatwill happen to my samples?
Wewill analyse samplesof the graft to determine either how theindividual
cells or the whole graft respondsto stimuli. ALL YOUR SAMPLES WILL BE
CODEDandonly this unique codewill be usedto identify the sample in the
laboratory. Identifiable information such as hospital numberand dateofbirth
will be stored in a secure database. The tissue sampleswill be considered to
be a gift to the Cardiothoracic Centre, which will act as a custodianof all of
the samples obtained as a result of these studies. As part of the ongoing
studies sampleswill be shared with researchers at the University of Liverpool
and rarely a small amount of your sample will be provided to other
researchers in the UK or other parts of the world. However,it is important to
rememberthat this will only be identified by a unique code.
In the short-term,it is unlikely that the samples will be of any commercial
value to the Cardiothoracic Centre or University of Liverpool — any
commercial valuein the futureis likely to be due to findings in groups of
patients rather than from samplesfrom a single patient.
Do | haveto take part?
It is up to you to decide whetheror not to give permission. Whetherornot
you give permission for these excess piecesoftissue to be used in our
researchwill not affect the standard of care you receive or your treatment in
any way.
What do | have to do?
If you decide to give your permission you will be given this information sheet
to keep and be askedto sign a consent form. If you decide not to give your
permissionthis is entirely at your discretion and you do not haveto give a
reason.
Will my taking part in this study be kept confidential?
If you consentto give permission for excesstissue to be usedin research, all
information that is collected about you during the course of the researchwill
be keptstrictly confidential. Any information about you which leaves the
hospital will have your name and address removed so that you cannot be
recognised from it.
Whatwill happento the results of the study?
Theresults of our research will be published in scientific journals over the
next few years. Youwill not be identified in any report or publication.
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Whois organising and funding the Research?
The programmeof researchis being organised by Doctors and Scientists in
the Research Department of the Cardiothoracic Centre. Someof the studies
within the programmeare funded by NHS Researchfunding and others by
charitable Institutions
Whohasreviewedthe study?
The Liverpool Research Ethics Committee has approved the following
studies within the research programme:
1. Nitric Oxide Generation And Mechanisms For Scavenging Reactive Oxygen
Species In Arterial And Venous Graft Endothelium.
2. Prevention of spasm in radial artery grafts
Contacts for further information
If you should require any further information you can contact membersof the
research team:
Mr Michael Shackcloth, Specialist Registrar, Cardiac Surgery (please contact
CTC switchboard)
Dr Paul Browning, Principal Clinical Scientist: Tel 0151 293 222
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CONSENT FORM
RESEARCH INTO VASCULARDISEASE AND BYPASS GRAFT FAILURE
AT THE CARDIOTHORACIC CENTRE
Pleaseinitial box
 
1. |confirm that | have read and understand the information sheet for the above study and   
have had the opportunity to ask questions.
 
2. |understand that my participation is voluntary and that | am free to withdraw at any time,   
without giving any reason, without my medical careorlegal rights being affected.
 
3. |understand that sections of any of my medical notes may be looked at by responsible   
individuals from the Cardiothoracic Centre or from regulatory authorities whereit is relevant to my
taking part in research. | give permission for these individuals to have access to my
records.
 
  4. | agree to take part in the above study.
 
Nameof Patient Date Signature
 
Nameof Person taking consent Date Signature
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Abstract
Background: Vasodilator strategies used to treat bypass grafts in the operating theatre, such as nitrates, phosphodiesterase inhibitors and
calcium channel antagonists have a broad butshort-lived effect against a variety of vasoconstrictor stimuli. Treatments that react irreversibly
with proteins modulating vasoconstriction have the advantage that their effects can last well into the postoperative period. In addition systemic
effects are avoided as the treatmentis localised to the treated graft. This study investigated the use of twoclinically applied drugs; fluphenazine
(SKF7171A, HCL), an irreversible calmodulin antagonist and minoxidil sulphate, an irreversible potassium channel opener. Treatments were tested
against receptor and non-receptor-mediated contraction in the humanradial artery. Method: Isometric tension was measured in response to
angiotensin Il, KCl and vasopressin in 108 radial artery rings (taken from 31 patients undergoing coronary artery bypass grafting). Control
responses were compared with rings pretreated with fluphenazine or minoxidil sulphate. Vasopressin responses were also compared in the
presence of glyceryl trinitrate or the reversible Rho kinase inhibitor Y27632. Results: Fluphenazine pretreatmentsignificantly suppressed
vasoconstriction to all agonists tested. Maximal responsesto angiotensinII, vasopressin and KCl were reduced by 42 + 19%, 35 + 8% and 48 + 15%
respectively, without any measurable effect on the ECs. Minoxidil sulphate showed no discernable effect. Vasopressin-induced contraction was
also reduced by high levels of glyceryltrinitrate (220 1M; 50 g/ml) or 10 ~M Y27632. Conclusions: The irreversible calmodulin antagonist
fluphenazinehaspotential to be developedas an inhibitor of contraction in arterial graft vessels. The involvement ofRho kinase indicates that
other vasoconstrictors and surgical stress can sensitize radial artery to vasopressin-induced contraction. Strategies targeting this pathwayalso
have future potential.
© 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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1. Introduction intravenously in the postoperative period to ameliorate
vasospasm, whichis believed to accountfor a proportion of
In coronary artery bypass graft surgery (CABG) superior
patient survival rates and increased freedom from major
adverse cardiac events have been obtained in patients
receiving left internal thoracic artery (ITA) grafts as
opposed to saphenous vein grafts [1]. These results have
encouraged surgeons towards a complete arterial revas-
cularisation strategy. Promising patency rates obtained
with the radial artery have now also established this graft
as a good alternative to the right ITA [2]. The radial artery
is a comparatively reactive graft and vasodilator strategies
are topically applied by many surgeons in theatre and
* Supported bythe British Heart Foundation and the Merseybeat Appeal(The
Cardiothoracic Centre, Liverpool, UK). MS was supported by a British Heart
Foundation Junior Research Fellowship (FS/03/057) during this project.
* Corresponding author. Current address: Physiology Dept, University of
Liverpool, CrownSt, Liverpool L69 3BX, UK. Tel.: +44 151 7945510;
fax: +44 151 7945517.
E-mail address: conant@liv.ac.uk (A.R. Conant).
early graft failures [2,3]. Vasodilator therapies include
combinations of nitrates, phosphodiesterase inhibitors or
calcium channel antagonists, and the recently introduced
irreversible a adrenoceptor antagonist phenoxybenzamine
[4,2,5]. The beneficial effects of this agent have been
shown in a recent prospective study. Patients receiving
phenoxybenzamine-treated grafts had a lower level of
perioperative myocardialinjury and a reducedincidence of
adverse cardiac events when compared to a verapamil/
glyceryl trinitrate treated group [5]. The strategy of using
an irreversible inhibitor is very attractive, since it means
that pharmacologically effective concentrations can be
applied selectively to the graft and the effect maintained
in the perioperative period without systemic complica-
tions.
Phenoxybenzamine has demonstrated the potential ben-
efits of irreversible antagonists in CABG as treatment
completely abolishes noradrenaline-induced contraction in
1010-7940/$ — see front matter © 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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radialartery for up to 16 hin vivo; unfortunately howeverthe
beneficial effects are limited to catecholamine-mediated
vasoconstriction [6—8]. Vasoconstrictors other than catecho-
lamines, released into the plasma in the immediate post-
operative period [9] can still reduce flow through the treated
graft [3]. Our aim was to test the potential for clinical
application of otherirreversible antagonists, with a broader
range of activity and the potential to inhibit both receptor
and non-receptor-mediated contraction in the radial artery.
Wetested twodrugs used currently in otherclinical settings,
fluphenazine and minoxidil sulphate. Fluphenazine is a cell
permeable, irreversible antagonist of calmodulin [10], the
cellular protein that translates an increase in intracellular
calcium into contraction. Minoxidil sulphate binds irrever-
sibly to the vascular ATP-sensitive K* channel (Karp channel)
and is used as an antihypertensive agent[11].
Radial artery produces stronger vasoconstriction than
ITA to virtually all vasoconstrictors studied [12—15];
however vasoconstriction is equivalent when normalised
to accountfor the different vessel diameters in most cases.
However, normalised responses to both angiotensin II and
vasopressin in the radial artery are stronger and more
sensitive than in the ITA, and occur irrespective of the
presence of endothelium [12,14,15]. In addition, vaso-
pressin-induced contraction in the radial artery is com-
paratively resistant to milrinone and glyceryl trinitrate,
two of the most commonly used vasodilator strategies [15].
The inhibition of the vasopressin-induced contraction in
radial artery grafts would be particularly advantageous for
surgeons, since they may wish to use vasopressin to treat
hypotension in the postoperative period [16]. In this study
we investigated the ability of fluphenazine and minoxidil
to inhibit contraction to vasopressin, angiotensin II and
high potassium. Vasopressin data were compared with
glyceryl trinitrate and with a Rho kinase inhibitor Y27632,
as the inhibition of Rho kinase has been shown to reduce
coronary artery vasospasm [17]. The potential of these
treatments, particularly fluphenazine, as graft treatments
in bypass surgery is discussed.
2. Material and methods
2.1. Sample preparation
Samples of radial artery were obtained from 31 patients
undergoing CABG at the Cardiothoracic Centre, Liverpool
NHS Trust, UK. The clinical characteristics of these patients
are givenin Table 1. The study was approvedby the Liverpool
Research ethics committee and informed consent was
obtained from each patient. The radial artery was harvested
with surrounding fat and the twosatellite veins. Depending
on the practice of the surgeons concerned, radial arteries
were treated in the theatre with either 1.6 mM papaverine
(Martindale Pharmaceuticals, Romford, UK) or 6 mM phenox-
ybenzamine (Goldshield Pharmaceuticals Ltd., Croydon, UK)
in a solution of the patients’ whole blood for 30 min. Arterial
sections surplusto surgical requirements werecollected from
theatre into Dulbecco’s Modified Eagle’s Media (Invitrogen,
UK) on ice and immediately transported to the research
laboratories.
 
Table 1
Clinical characteristics of patients
Total no of patients 31
Meanage (years) 63
Sex ratio (men/women) 23/8
Risk factors (n)
Smoking 6
Arterial hypertension 15
Diabetes mellitus 6
Preoperative treatment(n)
B-Blockers 22
Calcium-channelblockers 14
Nitrates 15
K+ openers 9
ACEinhibitors 11
 
2.2. Organ bath contraction studies
Radial artery sections were cut into 2—3 mm ringsgiving
108 rings in total. Arterial rings were suspended in
thermostatically controlled organ chambersat 37 °C, filled
with 25 ml Krebs—Henseleit buffer composed of 118 mM
NaCl, 4.7 mM KCl, 25 mM NaHCO3, 1.2 mM KH2PO,, 1.2 mM
MgSO,, 10 mM p-glucose, 1 mM CaCl,, gassed with carbogen
(95% O2/5% CO). Rings were mounted between wire
stirrups connected to a force transducer and changes
in isometric force recorded on a PowerLab 16SP data
recording system, connected to an Octal ML119 bridge
amplifier (ADInstruments Ltd., Chalgrove, Oxfordshire,
UK). Prior to stimulation radial artery rings underwent a
pretensioning protocol based on that described by He and
Yang [14]. Arterial rings were set at a pretension equivalent
to 100 mmHg, calculated from the internal circumference
and the wall tension derived from the Laplace relationship.
The tension was readjusted to the equivalent of 100 mmHg
every 20 min over a 40-min period. All rings were then
partially relaxed and left resting at approximately 90% of
their maximal circumference for 20 min prior to study. To
test for functional contractility, arterial rings were first
stimulated with 90mM KCl and all other responses,
including later KCl responses, expressed as % of this
response. Following surgical preparation and our contrac-
tion protocol, endothelial function, as evidenced by a
vasodilatory response to 10.M acetylcholine in rings
precontracted with 30 mM KCl, was foundto be negligible.
Responseswere terminated by washing with three complete
changesof media. Rings pretreated with fluphenazine-N-2-
chloroethane, diHCl (SKF7171A, HCl; Merck Chemicals Ltd.,
Nottingham, UK) were incubated in the presence of the
drug for 40 min at 100 uM, 10-fold greater than the ICs
concentration for calmodulin [10]. Rings treated with
minoxidil sulphate (Merck Chemicals Ltd.) were incubated
for 30min at 10M, a concentration reported to com-
pletely reverse noradrenaline-induced contraction in vas-
cular smooth muscle [18]. Following incubation with
fluphenazine or minoxidil sulphate the drug was removed
by three complete changes of media. Responses to
angiotensin II (Sigma, Poole, UK) were recorded within
20 min of drug washout and responses to Arg-vasopressin
(Sigma) at either 30 or 120 min. Responsesin treated rings
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were normalised to control rings stimulated in parallel and
pretreated with vehicle alone (dimethylsulphoxide; DMSO).
Y27632 (Merck Chemicals Ltd.) or glyceryl trinitrate (DBL,
Warwick, UK) were added to the organ chamber5 min prior
to and during agonist addition.
2.3. Data analysis
Data are presented as mean + standard deviation of the
mean (SD), where n refers to the number of independent
samples tested. The threshold vasopressin concentration was
defined as the concentration at which tension wassignifi-
cantly raised above baseline tension. Data were tested for
normal distribution and appropriate comparisons were
undertaken as the analysis dictated using a one-way ANOVA
and a Bonferroni correction for multiple comparisons. All
analyses werecarried out using the program Arcus QuickStat
Biomedical using a p value of 0.05 (Hearne Scientific
Software, Dublin, Eire).
3. Results
The internal diameter at a pressure of 100 mmHg
was 3.8 +0.9 mm. To test for functional vasoconstriction,
sections of human radial artery were stimulated with 90 mM
KCl that raised tension from a mean basal value of
1.93 + 0.92 g (n= 31) to 7.70 + 3.66 g. Data were collected
from distal arterial sections treated with phenoxybenza-
mine in theatre (6.26 + 2.18 g; n= 17) and proximal sections
treated with papaverine (9.72 + 4.49 g; n= 14). As pre-
viously reported by other investigators [19], proximal
sections gave significantly higher KCl-induced contraction
than distal (p < 0.05). All data were therefore expressed as
% of this initial KCl response.
3.1. Vasoconstrictor responses in radial artery
Robust concentration dependent contraction was
observed to vasopressin and angiotensin Il giving mean
maximal responsesof 109 + 10% KCl (n = 13; 95% confidence
interval 104—115) and 87 + 20% KCl (n = 14; 95% confidence
interval 104—79) respectively (Fig. 1a and b). When
expressed as % KCl, maximal responses to vasopressin
and angiotensin Il were not significantly different from
proximal and distal sections. Maximal responses to vaso-
pressin were also reproducible when arterial rings were
comparedfrom the same sample giving an average standard
deviation 6.3+4.0% for the response (n=5). Maximal
responses to angiotensin Il were more variable giving an
average standard deviation 15+8% for the response
(n= 3). Mean ECso values (—logi9 M) of 9.16 + 0.39 (95%
confidence interval 8.94—9.39) and 8.3340.52 (95%
confidence interval 7.93—8.73) were obtained for vaso-
pressin and angiotensin Il respectively. Whilst maximal
responses to both KCl and angiotensin Il returned to
baseline within 10 min following agonist washout, vaso-
pressin-induced contraction was completely reversed only
by glyceryltrinitrate. A mean ECso value for the reversal of
maximal vasopressin-induced contraction with glyceryl
trinitrate was 4.05 + 1.02 (—logi9 M; n= 6).
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Fig. 1. Representative traces from individual rings of radial artery showing
standard responses to increasing concentrations of either vasopressin or
angiotensin Il. Responses are shown in relation to an initial response to
90 mM KCI(A). Following washout (B) of the KCl response with two complete
changes of media, rings were stimulated with increasing concentrations of
either vasopressin (a) where C=0.1, D=0.3, E=1, F=10, G=30 and
H=100nM vasopressin) or angiotensin Il (b) where C=1, D=3, E=10,
F = 30 and G= 100 nM angiotensinIl).
3.2. Effect of treatments against vasopressin-induced
contraction
Pretreatment with fluphenazine consistently reduced the
maximal vasopressin-induced contraction (Fig. 2a; Table 2).
Wheninhibition was measured at 30 min (n= 3) and 140 min
(n= 3) after the drug had been washed out there wasnoloss
of effect. In addition, inhibition was identical in vessels
treated with phenoxybenzaminein theatre (n = 4) compared
to papaverine (n = 3). Arterial rings pretreated with minoxidil
failed to show any measurable inhibition (Fig. 2a; Table 2).
The effects of the Rho kinase inhibitor Y27632 were also
tested against vasopressin-induced contraction and com-
pared withglyceryl trinitrate (Fig. 2b). The addition of 10 uM
Y27632 to the organ chamber reduced the basal tension by
33 + 15% (n= 5) and resulted in a significant reduction in the
maximal vasopressin-induced contraction (Fig. 2b). Y27632
did not demonstrate any measurable effect on the ECsp of the
response for vasopressin and the degree of inhibition of
contraction was comparable to that produced by 220 uM
glyceryl trinitrate (Table 2). One consequence of the
inhibitory effects of Y27632 and glyceryl trinitrate was to
increase the threshold vasopressin concentration at which a
significant contraction could be measured from 0.1 to 1.0 nM
vasopressin.
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Fig. 2. Effect of treatments against vasopressin-mediated vasoconstriction.
Cumulative concentration response curves were obtained to vasopressin
following pretreatment (a) with vehicle alone (control; n= 12), 100 wM flu-
phenazine (n = 6) or 10 1M minoxidil sulphate (n = 6) or in the presence of(b)
10 uM Y27632 (n= 5) and 22 1M (n= 5) and 220 1M (n= 5) glyceryltrinitrate,
where n refers to the number of independent samples tested. Average
responses + SD, are shownrelative to a contractile response to 90 mM KCL
applied prior to treatment.
3.3. Effect of minoxidil sulphate and fluphenazine
pretreatment against angiotensin II and KCl-induced
vasoconstriction
Maximal responsesto angiotensin II werealso significantly
reduced by pretreatmentwith fluphenazine but not minoxidil
when comparedto controls (Table 3). No measurable change
Table 2
Table 3
Comparison of maximal responsesand affinity of response to angiotensinII in
humanradial artery pretreated with minoxidil sulphate or fluphenazine
Minoxidil Fluphenazine
Max response (% KCl) 80 + 28 54+ 20?
Confidence intervals (95%) 107-55 75-32
n q 6
ECs (—log M) 8.28 + 0.34 8.13 + 0.86
Confidence intervals (95%) 7.86—8.69 6.76—9.51
Data are expressed as % response to 90 mM KCl, where control responses to
angiotensin II were 87 + 20% with an ECsof 8.33 + 0.52 (n= 14). n refers to
the numberof independent samples tested.
* Denotessignificant differences (p < 0.05) between treatment groups and
controls by ANOVA using the Bonferroni correction for multiple comparisons.
in ECs9 values for vasopressin was observed with either
treatment. In addition, following fluphenazine treatment,
responses to 90 mM KCl were reduced by 48 + 15%, when
compared totheinitial KCl response. In control rings, KCl
responses were maintained, giving average values 107 + 21%
of the initial contraction (n = 8). Pretreatment with minoxidil
sulphate showed no measurable effect against KCl-induced
contraction giving an average response 112 + 17% (n= 6) of
the initial contraction.
4. Discussion
The majorfinding of this study was that pretreatment of
radial artery grafts with the calmodulin inhibitor, fluphena-
zine (SKF7171A), significantly attenuated receptor-mediated
contraction evoked by angiotensin II and vasopressin, and
depolarisation-induced contraction by high potassium. Cal-
modulin is the cellular protein, which integrates the calcium
response and activates the myosin light chain kinase
responsible for contraction. Since an increase in smooth
muscle calcium is the primary initiating stimulus for
contraction, this makes calmodulin an excellent target for
inhibiting contraction evoked by a wide range of agonists.
The true incidence of vasospasm in the humanradialartery is
difficult to determine as many cases may go undetected
[2,3]. Reports of perioperative ischaemia in patients with
radial artery bypass grafts [20] and the observed reduction in
postoperative markers of myocardial infarction in patients
receiving radial artery grafts treated with phenoxybenza-
mine as compared with those treated with verapamil/
glyceryltrinitrate [5], would support the need for effective,
postoperative vasodilator therapy.
Maximalresponses andaffinity of response to vasopressin in radial artery for treatment groups compared with vehicle treated controls
 
Minoxidil Fluphenazine Glyceryl trinitrate (22 4M) Glyceryl trinitrate (220 .M)
Max response (% KCl) 119 + 16 72 + 12? 94413? 99 +12 81411
Confidence intervals (95%) 134-105 81-63 110-79 114-83 95-68
n 7 7 5 5
ECsq (—log M) 9.13 + 0.32 8.90 + 0.35 8.81 + 0.33 8.78 + 0.43 8.56 + 0.38?
Confidence intervals (95%) 8.84—9.43 8.58—9.22 8.41—9.22 8.25—9.31 8.09—9.03
Data are expressed as % response to 90 mMKCL, wherecontrol responses to vasopressin were 108 + 11% with an ECso of 9.16 + 0.39 (n = 13). nrefers to the numberof
independent samples tested.
@ Denotessignificant differences (p < 0.05) when treatment groups were compared with controls by ANOVA using the Bonferroni correction for multiple
comparisons.
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The radial artery is a muscular artery with a larger
medial layer and a higher concentration of myocytes, when
compared with the ITA, and this is believed to underlie
its reactive nature [21]. In the immediate postoperative
period when circulating vasoconstrictor levels are still
elevated [9] systemic vasodilators are used by many
surgeons to minimise the potential for vasospasm. Strate-
gies include glyceryl trinitrate used either alone or in
combination with calcium channel antagonists and the
phosphodiesterase inhibitor milrinone [2—4]. A key obser-
vation is that fluphenazine inhibited vasopressin-induced
contraction by a similar extent to that of the maximal dose
of glyceryl trinitrate used. Since many of the samples used
in this study were already treated with the irreversible a
adrenergic antagonist phenoxybenzamine the effects of
fluphenazine are additional to those of phenoxybenzamine.
Phenoxybenzamine is now used by many surgeons and our
results suggest that fluphenazine can be used alongside
phenoxybenzamine, to provide inhibition to a broader
spectrum of stimuli.
Potent vasodilatation with nicorandil, a combined
potassium channel opener and nitric oxide donor, has
been reported against endothelin-mediated contraction in
radial artery [22]. Pinacidil, which shares a common
binding site with minoxidil sulphate and nicorandil on the
Karp channel, has also demonstratedits ability to reverse
phenylephrine-induced contraction in human radial artery
[23]. Therefore the activation of Karp channels would be
expected to reverse membrane depolarisation, inhibit
calcium influx across the plasma membraneand relax the
precontracted radial artery [11]. We found minoxidil
sulphate to be ineffective at inhibiting contractions in
the radial artery. This occurred irrespective of the use of
potassium channel blockers in the preoperative medica-
tion. Interestingly, minoxidil sulphate demonstrates a high
degree of tissue and species selectivity. For example,
minoxidil sulphate is a potent vasodilator in rat aorta but
not in rabbit aorta or rat mesenteric artery, whereas other
Karp Channel openers were equally effective in all tissues
[18]. The lack of effect measured in humanradial artery in
this study indicates that minoxidil sulphate has poor
activity in this vessel also.
The effect of the reversible Rho kinase inhibitor Y27632
was also investigated. Rho kinase controls the activation
state of the myosin light chain kinase responsible for the
phosphorylation of myosin. Activation of Rho kinase leads to
vasoconstriction at basal intracellular calcium levels in
smooth muscle [17]. This study demonstrated that Y27632
reduced the maximal vasopressin-induced contraction. Rho
kinase is activated by serotonin, endothelin 1 and thrombox-
ane A; [17] and bythe stress hormonecortisol [24]. Therefore
the involvement of the Rho kinase pathway in vasopressin-
induced contraction in the radial artery indicates that both
surgical stress and elevated levels of other vasoconstrictors
can increase the sensitivity of the graft to vasopressin. This
may be pertinent to the management of postoperative
contractionin radial artery grafts or the use of vasopressin in
the management of hypotension following CABG [16],
particularly as vasopressin-induced contraction in radial
artery is refractory to two of the most commonly used
vasodilator strategies [15].
4.1. Limitations of this study
This study demonstrated significant inhibition of both
receptor and non-receptor-mediated vasoconstriction in
radial artery with fluphenazine. Although effects were only
measured up to 2 h after treatment they would be expected
to be similar in duration to phenoxybenzamine, since
irreversible interactions of this type will last until the
smooth muscle cells of the vessel wall replace the inactivated
protein [7,8]. Inhibition with fluphenazine should therefore
last well into the postoperative period [8]; howeverit would
be useful to verify this in vivo. The animal model used to
confirm the duration of action of phenoxybenzamine would
suit this purpose [8]. Using this model it was demonstrated
that the effects of phenoxybenzaminelasted for 16 h in vivo
and we would expect a similar duration of action for
fluphenazine. In addition, calmodulin inhibition could also
affect the generation of endothelium-derived vasodilators.
Howeverthe generation of vasodilators by the endothelium is
not necessarily calmodulin-mediated [25] and it is unclear
how calmodulin inhibition would affect endothelium-depen-
dent vasodilatation in the radial artery. Interestingly, the
presence or absence of endothelium has been shown notto
influence vasopressin-induced vasoconstriction [15]; how-
ever, the effects of fluphenazine treatment on endothelium-
mediated vasodilatation should also be considered.
4.2. Conclusion
Fluphenazine has potential to be developed as a useful
treatment in graft vessels and demonstrates long-lasting
effects against vasoconstriction induced by several unrelated
agonists. Further studies are required to investigate the
duration and breadth of effect of fluphenazine against a
broader range of vasoconstrictors in radial artery. The
developmentof clinically useful Rho kinase inhibitors may
also provide a future therapeutic opportunity for the manage-
ment of arterial contraction in the postoperative period,
especially if Rho kinase inhibitors can be developed to give
long-lasting protection [17].
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